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Abstract

Parkinson's disease is caused due to the progressive loss of dopaminergic neurons
in the brain. Less than 10% of cases have a strict familial etiology while more than 90%
are sporadic. The mechanisms underlying neuronal cell death in Parkinson's disease have
not been fully elucidated. Furthermore, there is currently no therapy available to prevent
the progressive loss of neurons in Parkinson's disease. The objective of my research was
to establish a sporadic model of Parkinson's disease and evaluate the neuroprotective
effects of water soluble Coenzyme Qio. In this study, a model of paraquat-induced
neurodegeneration in rats was used to evaluate the efficacy of water soluble Coenzyme
Qio as a neuroprotectant. The results revealed a loss of dopaminergic neurons in the
substantia nigra pars compacta region of the brain in paraquat-injected rats. Increased
levels of oxidative stress and activated astrocytes were also observed in rats treated with
paraquat. Furthermore, the behavioural tests uncovered deficiencies in fine motor skills in
these rats. In parallel, rats that received water soluble Coenzyme Qio in their drinking
water showed significant neuroprotection against paraquat toxicity including behavioral
improvements, reduced loss of dopaminergic neurons and lowered levels of oxidative
stress. Interestingly, this neuroprotection was accompanied by an increased numbers of
activated astroglia in the midbrain. The ability of this formulation of Coenzyme Qio as a
therapeutic agent was also studied; preliminary results indicate that it offers
neuroprotection. Pilot studies revealed that paraquat-induced dopaminergic loss increases
with age. Altogether, this study confirmed the neurotoxicity of paraquat, especially
towards dopaminergic neurons, and provided a rat model of Parkinson's disease suitable
for mechanistic and neuroprotective studies. This is the first preclinical evaluation of
v

water soluble Coenzyme Qio as a neuroprotectant for Parkinson's disease at clinically
relevant doses.
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Chapter 1
Introduction

Parkinson's disease (PD) is characterized by the loss of dopamine producing
neurons present in the substantia nigra pars compacta region in the brain. Motor function
is affected in this disease. This chapter introduces the anatomy of the brain region
affected by PD, as well as the different dopaminergic pathways and the pathway
associated with PD. The causes of PD, the various models used for studying PD and the
mechanisms of cell death in PD are also addressed in this chapter. Lastly, the different
mechanisms underlying neuronal cell death in PD, and the neuroprotective strategies that
are used to treat people with PD are discussed.

1.1 The Basal Ganglia Circuitry
The basal ganglia (BG) consist of a large and functionally diverse set of nuclei,
which lie deep within the cerebral hemispheres. The subset of nuclei involved in motor
control include the caudate nucleus, putamen (caudate and putamen together form the
striatum), the globus pallidus: pars externa (GPe), and pars interna (GPi), subthalamic
nucleus (STN) and the substantia nigra (SN) (Bjarkam and Sorensen 2004) (Figure 1.1).
According to the classical model, the basal ganglia form a complex network that
integrates areas of the cerebral cortex, basal ganglia nucleus and the thalamus
(Alexander and Strick 1986). In this complex circuit, the neurons from the cortical areas
project into the striatum, especially the putamen. The striatum also receives projections
from the amygdala and hippocampus (Groenewegen 2003). These inputs into the
striatum are all excitatory. The transfer of cortical and thalamic information in the
1

striatum is modulated by dopaminergic inputs from the substantia nigra pars compacta
(SNc). The globus pallidus and the substantia nigra pars reticulata are the main sources
of output from the basal ganglia.
The signals for intentional movements are initiated in the cerebral motor cortex
and eventually reach the brain stem. From here they reach the muscles, but before they
do so, centers such as the cerebellum and the basal ganglia pose their influence on these
signals. Both these centers exert their influence on the final motor signals via the
thalamus (Groenewegen 2003).

CauCaie /
Nucleu#^

Cortex

'utamen

.Subthalamic
^Nucleus f

'pallidus
iubstantia \Mypotoaft
Nigra
\w j

Figure 1.1 A coronal section showing the components of the basal ganglia in
the human brain. The figure shows the arrangement of the caudate nucleus, putamen,
and globus pallidus relative to the substantia nigra, in the midbrain.
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The efferent projections from the striatum to the basal ganglia are segregated into
two pathways (for a representation of the basal ganglia circuitry, refer to Figure 1.2). In
the direct pathway, the neurons from the putamen directly project into the globus
pallidus pars interna and the substantia nigra pars reticulata (SNr). Neurons in this
pathway bear the D1 dopamine receptor subtype and provide a direct inhibitory effect on
GPi/SNr (Figure 1.2A). In the indirect pathway, the neurons from the putamen connect
with the GPi/SNr via the globus pallidus pars externa (GPe) and the subthalamic
nucleus. The neurons in this pathway have D2 dopamine receptor subtype, and cause the
excitation of GPi/SNr (Bjarkam and Sorensen 2004) (Figure 1.2B). Under normal
circumstances, the dopaminergic neurons present in the substantia nigra pars compacta
will supply dopamine to the striatum via the nigrostriatal pathway, stimulating neurons
expressing D1 receptors and inhibiting neurons expressing D2 receptors (Bjarkam and
Sorensen 2004). Thus the output from the basal ganglia is influenced by the opposing
effects of the direct and indirect pathways. An abnormal decrease or increase in the
activity of the basal ganglia output, is associated with Parkinsonism and dyskinesias
(Obeso et al. 2006).

3

A
Cortex

>t

Substantia
nigra pars
compacta

(Dl)
^

Putamen

Thalamus
>

f

Globus pallidus
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Substantia nigra
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Figure 1.2 The basal ganglia circuitry. The efferent projections from the striatum to the
basal ganglia are segregated into two pathways namely the direct pathway (A) and
indirect pathway (B).
4

1.2 Dopamine in the Nigrostriatal Tract
Dopamine is a member of the class of catecholamines, along with epinephrine and
norepinephrine. The first, and rate-limiting, step in catecholamine synthesis is the
enzymatic conversion of tyrosine to dihydroxyphenylalanine (DOPA) by tyrosine
hydroxylase (Figure 1.3). Dopamine is synthesized in the cytoplasm of the presynaptic
terminals and stored in vesicles by a vesicular monoamine transporter (VMAT). Upon
release in the synaptic cleft, its action is terminated by re-uptake into the terminal or
surrounding glial cells by the dopamine transporter (DAT) (Dziedzicka-Wasylewska
2004).
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Figure 1.3 Catecholamine synthesis. Dopamine functions as both a neurotransmitter
and a precursor for other catecholamines. Tyrosine hydroxylase is the rate-limiting
enzyme.
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Two enzymes are involved in the catabolism of dopamine: mitochondrial
monoamine oxidase (MAO) and cytoplasmic catechol-O-methyltransferase (COMT). The
final product of the breakdown of dopamine yields homovanilic acid (Figure 1.4)
(Dziedzicka-Wasylewska 2004).

Dopamine (DA)
Monoamine oxidase (MAO)
Aldehyde dehydrogenase

C atechol-O-methyltransferase (COMT)

HaC

3-Methoxytryamine (3-MT)

3,4-Dihydr oxyphenylacetic acid (DOPAC)

Monoamine oxidase (MAO)
Aldehyde Dehydrogenase

C atechol-0 -m ethyltransf erase (COMT)

Homovanilic acid (HVA)

Figure 1.4 Dopamine catabolism. Dopamine is broken down into homovanilic acid by
two different enzymes.
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1.3 Dopaminergic Pathways
Many of the dopaminergic neurons in the central nervous system are positioned in
the midbrain, and are divided into four functional and anatomical groups: mesolimbic,
mesocortical, nigrostriatal and tuberoinfundibular dopaminergic neurons. These circuits
are involved in the regulation of a wide range of processes, from circadian rhythms to
depression and reward-based behavior (Dziedzicka-Wasylewska 2004).
The mesolimbic pathway arises in the ventral tegmental area (midbrain) and
innervates the nucleus accumbens and olfactory tubercle in the ventral striatum and parts
of the limbic system including the septum, amygdyla and pyriform cortex. This pathway
is thought to be essential for motivated behaviours such as activity related to reward and
the positive reinforcement from frequently abused drugs, for instance alcohol, cocaine,
amphetamines and opiates. The mesocortical dopaminergic pathway also originates in the
ventral tegmental area and innervates the frontal, cingulate and entorhinal cortices. These
areas are involved in emotional, motivational and cognitive functions, such as certain
aspects of learning and memory. It is broadly acknowledged that the mesocorticolimbic
dopamine system plays a pivotal role in mediating acute rewarding effect of drugs of
abuse. Finally, the nigrostriatal pathway projects from the substantia nigra pars compacta
and innervates the dorsal striatum and is involved in motor control (DziedzickaWasylewska 2004). Imbalance in this pathway is associated with Parkinson's disease and
is associated with bradykinesia and hypokinesia (Groenewegen 2003).
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1.4 Parkinson's disease
Parkinson's disease (PD) is the second most prevalent neurodegenerative
disorder, and was first described by James Parkinson in 1817 (Schober 2004). The
prevalence of PD is 1-2 per 1000 (Bartels and Leenders 2009). The cardinal feature of
this disease is dopamine deficiency arising due to a progressive degeneration of
dopaminergic (DA) neurons in the nigrostriatal pathway. The dopamine neurons play an
important role in coordinating normal motor function. Post mortem studies have
revealed a decrease in the levels of dopamine and its metabolites in the different areas
including the globus pallidus, putamen, caudate, nucleus accumbens and the substantia
nigra of PD patients. Clinical symptoms such as resting tremors, bradykinesia, rigidity
and postural instability arise when about 60-70% of the DA neurons are lost, leading to a
decline in dopamine levels in the nigrostriatal pathway (Lang and Lozanol998).
Besides the dopaminergic defects, PD is assumed to be a multi-centric disease. It
is also believed that there is an association between the nigrost riatal degeneration and
degenerative process elsewhere in the central and peripheral nervous system. Three
possible scenarios are hypothesized: damage to the SNc and other regions occur
simultaneously, the disease primarily begins in the SNc and this influences the
involvement of other areas; or, the involvement of the SNc occurs later in the disease
(Lang and Lozano 1998). Lewy bodies are found in the degenerating DA neurons of PD
patients and are comprised of aggregated a- synuclein and ubiquitin (Bartels and
Leenders 2009).
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1.5 Etiology
The prevalence of Parkinson's disease (PD) in individuals over 50 years of age is
1 to 2% (Battels and Leenders, 2009 2009). Most cases (95%) are of unknown etiology
(Corti et al. 2005). Epidemiological studies have shown PD concordance rates to be
similar between monozygotic and dizygotic twins (50 years of age), indicating that
heredity is not a major etiologic component. Tanner screened 19,000 monozygotic and
dizyogotic twins for PD and found that there were very similar concordance rates
between the two types of twins (1989a). This result led Tanner to conclude that "genetic
factors do not play a major role in causing PD." Studies designed to understand the role
of environmental toxins explored geographic differences in PD prevalence. Evidence
pointed to a higher incidence of PD in industrialized nations. For example, PD
occurrence was correlated to exposure to industrial chemicals, quarries and printing
plants in China (Tanner et al. 1989b). Similarly, extensive pesticide use was associated
with increased incidence of PD in California. In fact, the incidence rate of PD between
1984 and 1994 was reportedly higher in California, a state which uses almost a quarter
of all pesticides in the US (Ritz and Yu 2000).

1.6 Models to Study Sporadic/Idiopathic Parkinson's disease
Much of the information regarding the etiology and pathogenesis of PD is obtained
from clinical studies, post-mortem studies, and epidemiological studies. Accessibility to
a human brain is limited because of ethical approval, availability of postmortem brain
tissue, and difficulty in drawing definitive conclusions due to individual variability and
differences in tissue quality (Emborg 2004). Animal models are therefore an important
10

tool to study the pathogenesis and strategies for therapeutic intervention of PD.
Parkinson's disease does not spontaneously develop in animals; therefore neurotoxic
agents have to be used to induce the characteristic functional changes associated with
PD. Ideally, animal models of PD should show all the clinical characteristics and
pathological features observed in people. Some of the prominent toxin-induced PD
models are discussed below.

1.6.1

MPTP Model
A major breakthrough in PD research came in the 1980's when a model to study

sporadic/idiopathic PD was accidentally discovered. In 1983 Langston and his
colleagues reported parkinsonian syndrome in young addicts that was clinically
indistinguishable from PD after injecting themselves with a synthetic narcotic. The
toxic compound was identified as

l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine

(MPTP) by chemical analysis. Post mortem analysis revealed selective loss of neurons
in the substantia nigra and Lewy-body-like inclusions. Intravenous use of MPTP caused
all the key signs of Parkinsonism. The striking similarities between sporadic PD and
MPTP-induced Parkinsonism suggested that compounds similar to MPTP in structure
or biological activity might be the primary cause of sporadic PD (Smeyne and JacksonLewis 2005).
MPTP by itself is not toxic. It is a lipophilic compound that easily crosses the
blood brain barrier upon administration. MPTP is converted to its toxic metabolite 1methyl-4-phenyl pyridinium ion (MPP*) by monoamine oxidase B especially in non-
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dopaminergic cells such as astrocytes (Di Monte 2003, Przedborski and Vila 2003,
Schober 2004). Figure 1.5 illustrates the metabolism of MPTP.
DOPAMINERGIC NEURON

ASTROCYTE
MPTP

MPTP
CELL DEATH
MPDP
OXIDATIVE STRESS

MPP*

MPP*

BRAIN

Figure 1.5 Metabolism of MPTP in glial cells. In the presence of monoamine oxidase,
l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine (MPTP) is converted to l-methyl-4-phenyl
pyridinium ion (MPP+) which is the toxic to the dopaminergic neurons.

MPP+ is a substrate for the vesicular monoamine transporter (VMAT), which
translocates MPP+ into synaptosomal vesicles, and also for the dopamine transporter
(DAT) present on dopaminergic neurons and for norepinephrine-serotonin transporters.
(Javitch et al. 1985, Daniels and Reinhard 1988, Przedborski and Vila 2003). Upon
entering a dopaminergic neuron, MPP+ can be concentrated by an active process within
the mitochondria where it impairs electron flow through the electron transport chain by
inhibiting complex-I.
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MPTP induces the symptoms of PD in rodents, cats, non-human primates and
mini-pigs (Terzioglu and Gaiter 2008). Neuropathological studies in humans and
monkeys indicate that MPTP induces damage to the dopaminergic neurons in the
nigrostriatal pathway identical to that seen in PD (Bove et al. 2005). MPTP is usually
administered systemically (subcutaneous, intraperitonial, intravenous or intramuscular).
In non-human primates, unilateral intracarotid infusion of MPTP is often used to
administer the drug. Susceptibility to this compound varies in different species. A
multitude of regimens and doses of MPTP (acute, chronic) are used to study PD (Betarbet
et al. 2002). Acute MPTP administration induces specific degeneration of dopaminergic
neurons in the substantia nigra (between 50 and 93% loss) while chronic administration
of MPTP induces about 50-60% loss of dopaminergic neurons (Betarbet et al. 2002).
Although numerous studies with MPTP have been conducted in monkeys, molecular
mechanisms underlying MPTP-induced toxicity are largely studied in rodents such as
mice (systemic injections) and, albeit to a lesser extent, in rats (intracerebral injections)
(Bove et al. 2005).
Neurochemical changes that accompany MPTP exposure include decreased levels
of dopamine and its metabolites in the striatum as well as and increased oxidative damage
(Betarbet et al. 2002). Systemic MPTP administration in mice induces PD-like
symptoms, including bradykinesia, rigidity and posture anomalies. These symptoms
parallel the low dopamine neuron counts that also result due to MPTP exposure (Sedelis
et al. 2001). Studies have also investigated the role of MPTP on motor behaviour
including locomotion, circling, rearing and/or stereotyped behaviour (Sedelis et al. 2001).
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1.6.2 Pesticide/ Herbicide Induced PD Models
Several epidemiological studies have revealed a link between environmental
factors such as farming and exposure to chemicals used in agriculture, and increased
incidence of PD (Tanner et al. 1989b). A number of environmental stimuli are
associated with the disease including herbicides, pesticides, cyanide, carbon monoxide
and heavy metals (Uversky 2004). Over the years there has been an increased focus on
the association between pesticide exposure and incidence of PD. Studies have shown a
strong correlation between long term pesticide exposure and increased risk of PD
(Brown et al. 2006). It has been hypothesized that many chemicals used in agriculture
are capable of selectively targeting dopaminergic neurons, thereby accelerating the
development of PD. In order to better understand the role of environmental toxins in
PD many toxin-based models have been developed.

1.6.2.1 Paraquat Model of PD
Paraquat (PQ), or 1, l'-Dimethyl-4, 4'-bipyridinium, is a quaternary nitrogen
herbicide commonly used to kill broad leaf weeds. Although banned in the United States
and countries of the European Union, it is still used in many developing countries. For
many years, experimental studies using PQ focused on its deleterious effects on the lungs,
liver and kidneys because acute exposure can induce toxicity and even death (Bove et al.
2005). Epidemiological studies in Taiwan, where PQ is commonly sprayed on rice fields,
showed that people exposed to PQ for at least 20 years had almost a 600% higher chance
of developing PD (Liou et al. 1997). These studies raised the possibility that PQ could be
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an environmental Parkinsonian toxin. Also interesting to note is that the structure of PQ
is strikingly similar to that of MPP+ (Figure 1.6).
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Figure 1.6 The chemical structures of PQ, MPP+ and MB.
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Paraquat is a hydrophilic, charged molecule and therefore does not diffuse across
cell membranes, including the blood brain barrier (Dinis-Oliveira et al. 2006). Studies
have shown that PQ enters the central nervous system through neutral amino acid
transporters located in the blood brain barrier (McCormack and DiMonte 2003). Co
administration studies using PQ and competitive inhibitors of neutral amino acid
transporters (e.g., L-valine, L-phenylalanine, L-dopa), revealed a prevention in PQ
induced neurotoxicity (McCormack and DiMonte 2003).
The cellular toxicity of PQ is mainly due to its' ability to participate in reactions
that produce reactive oxygen species (ROS). In the cell, PQ is reduced to form a
monocation free radical (PQ*4) by either NADPH-cytochrome P450 reductase (Clejan
1989), cytochrome c reductase (Fernandez et al. 1995), or complex I of the mitochondrial
electron transport chain (Fukushima et al. 1993) (Figure 6). The monocation free radical
form of PQ then reacts with oxygen to form a super-oxide radical (O2 "). Once the super
oxide radical is formed, it can react through well known mechanisms to create other
reactive oxygen species, all of which are harmful to cells (Dinis-Oliveira et al. 2006).
Moreover, it is believed that the redox cycling process of PQ depletes intracellular stores
of NAD(P)H due to its increased oxidation, thus contributing to the toxicity of this
herbicide (Dinis-Oliveira et al. 2006). PQ*+ can also reduce iron (III) and iron (III)
chelates, in turn catalyzing the formation of hydroxyl radicals via the Fenton reaction
(Hastings 1995). PQ, like MPTP has been used to induce PD in rodents (mice and rats) as
well as in monkeys (Bove et al. 2005). Systemic exposure to PQ in mice and rats results
in loss of dopaminergic neurons especially in the SN region, and reduction in the density
of striatal TH-fibres (von Bohlen und Halbach et al. 2004). Intraperitonial injections of
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10 mg/kg PQ in mice have shown to create a selective loss of dopaminergic neurons in
the SN region (McCormack et al. 2002).
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Figure 1.7 Reduction-oxidation cycling of PQ. PQ is reduced to form a monocation
free radical (PQ*+) by either NADPH-cytochrome P450 reductase cytochrome c
reductase, cytochrome c reductase, or complex I of the mitochondrial electron transport
chain. The monocation free radical form of PQ then reacts with oxygen to form a super
oxide radical (02* ).
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Early studies of PQ-induced PD in animal models were unsuccessful in observing
any changes in the nigrostriatal DA pathway following systemic exposure to PQ (Bove et
al. 2005). However, with the introduction of stereological cell counting following sub
lethal dosing of PQ over a 3-week period shows a decrease in TH-positive cells in the
SNc. In addition, DA neurons in the SN and striatum appear particularly sensitive to PQ,
as other subpopulations of neurons were unaffected (Bove et al. 2005). Reduced motor
activity and dose dependent losses of striatal DA nerve fibres were also reported in mice
receiving multiple PQ injections (Brooks et al. 1999). While no significant depletion of
striatal DA has been observed following PQ injections in vivo, evidence for enhanced DA
turnover is suggested by increases in TH activity and altered DA metabolite levels
(McCormack and DiMonte 2003).
Additional evidence to support the status of PQ as a parkinsonian toxin comes
from data indicating upregulation and aggregation of a-synuclein within SNc neurons in
treated mice (Manning-Bog et al. 2002). Significant amplification in 4-hydroxynonenol
positive neurons and nitrotyrosine immunoreactivity in nigral cells of PQ-treated mice
provide further evidence for oxidative injury in the SNc (McCormack et al. 2005).
Although PQ exerts its toxicity via oxidative stress, it also triggers the activation of cJun-N-terminal kinase (JNK) and caspase-3 in both in vitro and in vivo conditions,
suggesting that JNK pathways could mediate paraquat-induced neurodegeneration (Peng
et al. 2004).

18

1.6.2.2 Paraquat-Maneb Model: The Multi-hit Hypothesis
Most studies identifying environmental toxins that target DA neurons have
focused on the use of a single chemical to induce PD. Nonetheless, humans may be
exposed to multiple toxins in their environment. The multi-hit hypothesis proposes that
the brain is able to resist the effects of an individual chemical that targets DA neurons;
however, the defence machinery may be compromised when several toxins target
different sites in the DA system, ultimately leading to neuronal damage and cell death
(Brown et al. 2006). Of the different models using combinations of toxins to study PD,
the PQ-Maneb combination has been shown to act synergistically to induce PD-like
pathology. Maneb is a commonly used fungicide (for structure, refer to Figure 1.6).
Studies using a combination of Maneb (MB) (30 mg/kg) and PQ (10 mg/kg) have shown
greater neuronal damage than what is induced by either chemical alone (Cory-Slechta et
al. 2005). The PQ-MB model has been used to study the effect of exposure to multiple
environmental neurotoxins on the risk for PD development (Thiruchelvam et al. 2000a).

1.7 Molecular Mechanisms Contributing to Toxin-induced Neurodegeneration in
PD
The mechanisms involved in the progressive loss of dopaminergic neurons in PD
are of foremost interest in the field of PD. Though the exact mechanism of neurotoxicity
is not yet fully known, oxidative stress, mitochondrial dysfunction, excitotoxicity and
neuroinflammation are all believed to play an important role in the death of SN neurons.
These mechanisms are discussed below.
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1.7.1

Oxidative Stress
Mounting evidence supports the theory that oxidative stress may contribute to PD

pathogenesis (von Bohlen und Halbach et al. 2004). The brain depends mainly on
energy produced from the mitochondria, and approximately 95% of the molecular
oxygen that is inhaled is metabolized by the mitochondrial electron transport chain.
This causes the mitochondria to be exposed to high levels of reactive oxygen species
(ROS) and oxidative stress that can damage distinct neuronal populations (Tritschler et
al. 1994).
High levels of ROS cause oxidative stress, which refers to the undue oxidation of
biomolecules leading to cellular damage. ROS include a number of reactive molecules
derived from oxygen (Valko et al. 2007). Stepwise reduction of molecular oxygen
leading to the formation of ROS like superoxide and hydrogen peroxide is shown in
figure 1.8.

02^* 0:"-k. H^ChivOH + OH -k. 2H;0
2H+

2H*

Figure 1.8 Stepwise reduction of molecular oxygen.
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Production of the superoxide anion radical occurs mostly in the mitochondria and
it is converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 is not
a free radical but can penetrate cell membranes making it very toxic to the cell. In the
presence of iron, the Fenton reaction converts H2O2 to the OH* radical. This radical is
likely capable of causing more damage than any other ROS (Betteridge 2000). These
oxygen radicals can induce mitochondrial dysfunction, accelerating the production of
more reactive oxygen species, thereby escalating and perpetuating the vicious cycle (von
Bohlen und Halbach et ah 2004). Additionally, superoxide radical can react with nitric
oxide (NO) to form peroxynitrite anion (ONOO ), which is highly reactive and can be
neurotoxic (von Bohlen und Halbach et ah 2004).
ROS can react with proteins, DNA and lipids. In vitro studies revealed that ROS
can directly react with several amino acid residues leading to less active enzymes and
malfunctioning proteins. ROS can cause modifications in DNA leading to mutagenesis.
ROS have also been shown to target mitochondrial DNA. In many cases apoptosis, a
form of programmed cell death is mediated by ROS (Valko et ah 2007).

1.7.1.1 Oxidative Stress in PD
The contribution of oxidative stress in PD nigral cell death has been demonstrated
by post-mortem studies in PD patients as well as by toxin-induced PD models (Jenner
2003; Dickson 2007). Even under normal conditions, the substantia nigra (SN) region is
subjected to oxidative stress due to production of ROS during dopamine metabolism,
high levels of essential cofactors iron and copper for catecholamine metabolism, and/or
high levels of oxidized GSH (Spina and Cohen 1988, Dickson 2007). Dopamine
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autooxidation leads to production of H2O2, which is converted to the extremely toxic
hydroxyl radical (Youdim et al. 1989) (Figure 1.9).
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Figure 1.9. Dopamine autooxidation. Autooxidation of dopamine leads to the
production of superoxide anion radicals, which can then be converted to hydroxyl radical.
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Post mortem studies of PD patients have shown higher than normal iron levels in
the SN region (Andersen 2004).
Although ROS levels cannot be measured directly, the assessment of their
reaction products and the concomitant damage in post mortem tissues serve as indirect
evidence of increased or decreased levels. The evidence for increased oxidative damage
include increased levels of lipid peroxidation, DNA damage and protein oxidation
observed in the SN region in PD patients (Sanchez-Ramos 1994, Yoritaka et al. 1996,
Alam et al. 1997a, Alam et al. 1997b, Floor 1998, Zhang et al. 1999). In the brain, GSH
is known to play a vital role in detoxification of ROS (Dringen 2000). A decrease in the
levels of reduced GSH by about 50% in PD substantia nigra is also evidence of increased
oxidative stress (Perry 1982, Perry 1986, Riederer 1989, Beal 2003a). Lower glutathione
content appears to be the earliest marker for oxidative stress during the progression of PD
(Nakamura 1997).
Interestingly, nitric oxide (NO) can cause nitrosative damage by displacing iron
from ferritin, leading to degeneration of the cells in PD (Beckman et al. 1990, Reif and
Simmons 1990, Shergill et al. 1996). NO inhibits glutathione reductase and also causes
DNA single-strand breaks and increases DNA oxidation (Sanchez-Ramos 1994, Alam et
al. 1997a, Barker et al. 1996). It is known that parkin has ubiquitin-3 ligase like activity
and S-nitrosylation of parkin may impair its ability to ubiquitinate proteins (Schapira
2008). NO also inhibits the mitochondrial respiratory chain and enhances damage caused
to the mitochondria by toxins such as MPP+ (von Bohlen und Halbach et al. 2004).
It is yet to be determined which of the two species, ROS or reactive nitrogen
species (RNS), is the main culprit in the development of PD. Furthermore, oxidative
stress is linked to other cellular processes such as cell death, inflammation, excitotoxicity
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and mitochondrial dysfunction, so it is not easy to establish whether oxidative stress is
the primary initiating agent or a product of these events (Jenner 2003, Andersen 2004).

1.7.2 Mitochondrial Dysfunction in PD
Mitochondria are the primary site for energy production, which is regulated by
five respiratory complexes. There is mounting evidence suggesting the involvement of
mitochondrial dysfunction and impairment of complex I in the onset of PD (Koller and
Cersosimo2004). Many environmental toxins including rotenone, MPP+ and PQ are
known to inhibit complex I of the mitochondrial electron transport chain (Fukae et al.
2007). Studies involving toxin-induced PD in animal models have revealed a loss in the
activity of complex I by MTPT and rotenone. Post mortem studies of PD patients
indicate a 30-40% loss of activity of complex I in the SN region (Bove et al. 2005).
Reactive oxygen species (ROS) such as the superoxide anion radical can
reversibly and irreversibly inhibit complexes I and IV, and although the mechanism of
action of reactive nitrogen species (RNS) remains vague it is hypothesized that NO may
be involved in the S-nitrosylation of thiol groups in these complexes (Barker et al. 1996)
Mitochondria

are

responsible

for

generating

ATP

through

oxidative

phosphorylation and mitochondrial dysfunction caused by oxidative stress can lead to a
decrease in ATP production, which may contribute to cell degeneration in PD (Andersen
2004). Indeed, in vitro studies in our lab indicate that oxidative stress causes a decline in
mitochondrial ATP production in neuroblastoma cells (McCarthy et al. 2004). Reduced
ATP levels causes inhibition of PA700, an activator of the 26S proteasome, resulting in
decreased ubiquitination (Jenner 2003). Additionally, mitochondrial dysfunction leads to
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the failure of ATP-dependent magnesium inhibition of N-methyl-d-aspartate (NMDA)
receptors thereby escalating vulnerability to excitotoxicity (Koller and Cersosimo2004).

1.7.3 Excitotoxicity in PD
There is no direct evidence to implicate excitotoxicity in PD; however, it has been
suggested that glutamate may have a toxic effect on DA neurons in the SN region since
this region receives glutaminergic projections from the subthalamic nucleus (STN)
(Groenewegen 2003, Henchcliffe and Beal 2007). Under physiological conditions in
striatum there exists a neurotransmitter balance between the activation of striatal
neurons through N-methyl-D-aspartate (NMDA) receptors and inhibition by the D2
dopamine receptors. In PD patients, depleted nigrostriatal dopamine results in
disinhibition of the neurons in the striatum and therefore leads to glutamatergic
overactivity (Lang and 0beso2004a). Due to increased glutamate binding onto the
NMDA receptors, there are changes in cell permeability to calcium. The pathological
activation of NMDA receptors causes massive Ca2+ entry into neurons, where Ca2+
accumulates in the mitochondria. Matrix Ca2+ accumulation is proposed to produce
high levels of superoxide and other reactive oxygen species that damage the
mitochondria and thus the cell, ultimately causing neuronal cell death. The two
mechanisms involved in calcium dependent NMDA neurotoxicity are: excessive nitric
oxide (NO) formation and mitochondrial dysfunction (von Bohlen und Halbach et al.
2004).
Increased activity of glutamate in the STN has been reported in animal models
and post-mortem studies (Symeyne and Jackson-Lewis 2005). MPTP induced animal
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models of PD have shown altered glutamate activity, while co-injection of MPTP with
glutamate antagonists offered protection to DA neurons from the deleterious effects of
glutamate (Symeyne and Jackson-Lewis 2005).

1.7.4

Neuroinflammation in PD
The role of inflammation in neurodegenerative diseases such as PD is not well

understood and the events triggering an inflammatory response in the brain are unclear.
Glial cells are the most abundant cells in the brain and make up 90 percent of the cells
in the brain. These cells do not carry nerve impulses. However, they perform many
important functions, including providing physical and nutritional support for neurons.
Different types of glial cells exist, which include Microglia, Oligodendroglia, Astroglia,
Schwann's Cells, and Satellite Cells (Mena and De Yebenes 2008).
Astrocytes are the most abundant glial cells, and are considered to be critical for
neuronal support, nutrition, eliminating toxic compounds, and production of neurotrophic
substances. Astrocytes are of interest to PD researchers because PD patients have a lower
number of astrocytes in the substantia nigra (SN) than in other brain areas (Mena and De
Yebenes 2008). It is hypothesized that DA neurons of the SN region have increased
susceptibility to toxic insults because they are less protected than neurons of other
regions. DA neurons spontaneously produce free radicals during the metabolism of
dopamine, and the astrocyte guardian cells that offer protection from oxidative stress
have high free radical scavenging properties (Mena and De Yebenes 2008). Indeed, there
is evidence

to suggest that astrocytes support the differentiation, survival,

pharmacological properties, and resistance to injury of DA neurons. Dysfunctional
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astrocytes enhance neuronal degeneration by a diminished secretion of trophic factors.
Glial cells can also instigate damage of nigrostriatal DA neurons via the release of
cytokines and amplified production of reactive oxygen molecules (Mena and De Yebenes
2008).

Over the last decade the concept of "neuroinflammation" has become more
accepted in the field of neurodegenerative diseases, and particularly in PD (Mena and De
Yebenes 2008). There is an abundance of reactive astrocytes and reactive microglia in the
SN of PD patients, indicating a robust inflammatory state (Mena and De Yebenes 2008).
Glial cells are normally neuroprotective but given adverse stimulation, they may possibly
contribute to chronic inflammation. Microglia, the phagocytes of brain, might be the main
contributors of inflammation as they can produce large amounts of superoxide anion
radicals and other neurotoxins (Mena and De Yebenes, 2008). Oligodendrocytes do not
seem to play a part in promoting inflammation but may be sensitive to damage by
inflammatory processes (Mena and De Yebenes 2008).
In PD, degeneration of dopaminergic neurons is coupled with a drastic increase in
microglial activity, which could be a consequence of neuronal cell death or due to
participation of microglia in the cell death process (McGeer and McGeer 1999). Altered
glial function contributes to the demise of DA neurons as observed upon co-incubation of
these neurons with toxins such as MPTP and 6-hydroxydopamine (6-OHDA) (McNaught
and Jenner 1999). The detection of elevated levels of pro-inflammatory cytokines and
increased oxidative stress induced damage in post mortem PD patient samples suggests
that microglial activation plays a significant role in the degenerative process leading to
PD (Teismann and Schulz 2004).
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McGeer et al. reported that the response of glial cells is more robust in the SN
than the striatum, albeit damage to DA neurons is more severe in the striatum (1999).
Microglia become activated in the brain, proliferate and start expressing noxious
molecules such as ROS, RNS, cytokines and pro-inflammatory prostaglandins in
response to various insults (Kreutzberg 1996). Amplified levels of pro-inflammatory
cytokines such as tumor necrosis factor alpha (TNF-a) and interleukin-ip (IL-ip) have
been observed in the cerebrospinal fluid and striatum of PD patients (Mogi 1994). These
cytokines are potent activators of inducible nitric oxide synthase (iNOS) in rodents
(Teismann and Schulz 2004). Cytokines released from glial cells bind to their specific
receptors found on DA neurons. Upon binding to their corresponding receptors, these
cytokines can trigger apoptosis by activating caspase-3 via the extrinsic pathway
(Hartmann et al. 2000)
All of these cellular events play an important role in the progression of PD. There
is a complex inter-relationship that exists, making it is very difficult to elucidate the
initiating event.

1.8 Advances in Therapeutic Approaches for PD
There are several options available for the potential treatment of PD. Current
therapies are symptomatic and focus on treating the symptoms of PD. These include
dopamine replacement strategies, non-dopaminergic pharmacological therapies, surgical
approaches (directed at improving motor function, or at replacing striatal
dopamine/dopaminergic neurons), and neuroprotective therapies. Undoubtedly, these
therapies have significantly improved the quality of life and survival of PD patients;
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however, with disease progression clinical features emerge that cannot be controlled
with available medical or surgical therapies (Olanow 2008). The development of a
neuroprotective therapy that slows, impedes, or ideally reverses neurodegeneration
occurring in Parkinson's disease is a most important and fruitful area of research but
also the area most abounding in failures (Lang and 0beso2004b).
Surgery is an option held in reserve for complex cases of PD in which motor
complications or medical intolerance has led to a drastic decline in quality of life (Savitt
2006). Surgery for Parkinson's disease may involve destruction of certain parts of the
brain (thalamus, the globus pallidus and the subthalamic nucleus) or insertion of
electrodes into these areas for electrical stimulation. Cell transplantation to replace
striatal DA neurons is under investigation even though there are many technical and
methodological issues (Lang and 0beso2004b). Many studies in rodents indicate that
embryonic mesencephalic cell grafts can survive, reverse dopamine deficit and even
compensate for the behavioural disturbances arising from depletion of dopamine. Clinical
trials using embryonic mesencephalic cell grafts on PD patients have increased survival
and can secrete dopamine in response to pharmacological stimuli (Lang and
0beso2004b).
Pharmacological replacement of dopamine with dopamine agonists, such as
Levodopa (L-dopa), is the most effective symptomatic treatment for PD (Olanow 2008).
Although L-dopa is extremely effective; there are two main concerns with its long-term
use. The first relates to the toxicity of L-dopa to dopamine neurons; L-Dopa can generate
harmful reactive oxygen species (ROS) by oxidative metabolism of dopamine or via
autooxidation, which may hasten the rate of degeneration in PD. The second concern is
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the high frequency of motor complications associated with chronic L-dopa treatment
(Olanow 2008).
There is ample evidence for the role of inflammation in PD. Numerous casecontrol studies suggest that people who use non-steroidal anti-inflammatory agents have a
lower risk of developing PD. Many neuroprotective agents such as monoamine oxidase
(MAO-B), inhibitors such as rasagiline, anti-excitatory drugs such as glutamate
antagonists, and trophic factors such as GDNF have been studied for their potential as
possible therapeutics (Olanow 2008). Bioenergetic compounds such as creatine,
riboflavin, nicotinamide and Coenzyme Qio (C0Q10) are potential candidates as
neuroprotective agents for PD (Beal, 2003b).

1.8.1 CoQio as a Neuroprotective Agent
Coenzyme Qio (CoQio) is a hydrophobic, naturally occurring compound that
transfers electrons from complex-I and complex-II to complex-Ill of the mitochondrial
electron transport chain. It is a very important antioxidant in the mitochondria as it
readily scavenges free radicals (Beal 2003b). The redox cycling of CoQio is shown in
figure 1.10. CoQio also called ubiquinone can accept one electron and form a
semiubiquinone radical, which can then accept one more electron to get reduced to
ubiquinol.
Neuroprotective effects of CoQio in the central nervous system have been
demonstrated in vivo by the prevention of reduction in the GSH and ATP levels, as well
as protection during experimental ischemia (Beal 2003b). An open-label phase trial of
CoQio in PD patients found good CoQio absorption and tolerability. Although
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encouraging results were obtained from this study, Beal and his colleagues have
cautioned that the data is preliminary and would only recommend that PD patients take
a high dosage of C0Q10 once a larger trial has been completed (Beal 2003b).
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Figure 1.10 The oxidized and reduced forms of C0Q10. The oxidized form of C0Q10
(ubiquinone) can accept one electron to form the semiubiquinone radical, which can
accept one more electron to form the reduced form of C0Q10 (ubiquinol).
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A major drawback in working with C0Q10 is that it is very lipophilic and so
studying its protective properties in cell culture is difficult due to its hydrophobic nature;
however, through a patented protocol (US patent #6 045 826) a water-soluble formulation
of CoQio (WS-CoQio) was developed by Sikorska and Borowy-Borowsky of the National
Research Council of Canada. Vitamin-E and polyethylene glycol have been used as
carriers to solubilize CoQio and help in the uptake of this compound by the cells. Studies
aimed at evaluating the bioavailability of this formulation established that cells were
capable of internalizing WS-CoQio when it was added to the media as an aqueous
solution (Borowy-Borowski et al. 2004). A 3-day exposure to 10 ng/ml of WS-CoQio,
caused an increase in cellular mitochondrial membranes and cell membranes. The
treatment also caused an increase in total cellular levels of ATP (Sandhu et al. 2003).This
formulation has effectively been used to prevent oxidative stress induced cell death
(McCarthy et al. 2004, Somayajulu et al. 2005). Protection by WS-CoQio of
differentiated neuronal cells against cell death induced by glutamate excitotoxicity was
also reported (Sandhu et al. 2003). Recently, WS-CoQio was shown to inhibit Bax
activity and thus prevent Bax-induced destabilization of mitochondria in mammalian
cells (Naderi et al. 2006). I have shown WS-CoQio to be protective against PQ-induced
toxicity in vitro; therefore evaluatation of the efficacy of WS-CoQio in vivo was the next
step. This project is focussed on evaluating the efficacy of this unique formulation of
CoQio in preventing dopaminergic (DA) cell death occurring in PD.
Studies in my lab have shown that PQ induces neuronal cell death (McCarthy et
al. 2004) and pre-treatment of these cells with WS-CoQio can prevent PQ mediated cell
death in vitro. I have tested the efficacy of this compound in two different cell lines and
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using different insults. The results from the in vitro work were very encouraging and
therefore roused interest to test the efficacy of this compound in vivo.
As mentioned earlier, occurance of sporadic PD is correlated with exposure to
toxins. Toxin induced PD model could be a good model to study the efficacy of the water
soluble formulation of CoQio- As described before, many mice models of PQ induced PD
are used, but there is a lack of behavioural outcomes in these models. I wanted to
establish a model to assess the deficits in motoer and balancing behaviour. This project is
a collaborative work between the department of Biochemistry and Pschology at the
University of Windsor, Ontario. Dr. Cohen, our collaborator has a well established
pschology lab where he uses rats to study different behaviours. Since there exists a
functional lab to assess behavioural outcomes in rats, they were the ideal choice for a
sporadic PD model for this study.
Previous work has shown that PQ causes oxidative stress induced cell death of
DA neurons and WS-C0Q10 helps prevent this loss of neurons. PQ induces selective loss
of dopaminergic iof the neurons in the SNc. Toxin-induced sporadic models of PD have
been developed, where exposure to toxins such as herbicides can lead to the loss of
dopaminergic neurons in the SNc. PQ-induced PD models have been well characterised
in mice (McCormack et al. 2002) in which the neurodegenerative changes induced by PQ
are dose-dependent and differentially affect specific cell populations (McCormack et al.
2002, Manning-Bog et al. 2003). Our working hypothesis was based on the fact that PQ
induces death of DA via oxidative stress and mitochondrial dysfunction. WS-CoQio can
prevent mitochondrial dysfunction as observed in in vitro studies previously. If animlas
are fed with this formulation, it can provide resistance aginst PQ mediatd toxicity. Since a
behavioural component is used to assess motor damage, PQ mediated DA degeneration
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would lead to motor and balance deficits. If WS-C0Q10 is neuroprotective, it would result
in redox balance favouring low oxidative stress, decrease the number of DA neurons
undergoing cell death, and ultimately reduce the motor and balance deficits induced by
PQ.

1.9

Objectives

The objectives of this research are to:
1. Develop a paraquat-induced sporadic Parkinson's disease model in Long Evan's
hooded rats.
2. Assess the neuroprotective effects of water soluble Coenzyme Qio (WS-CoQio)
by evaluating behavioural, biochemical and histochemical parameters and to
evaluate the mechanism of neuroprotection offered WS-CoQio.
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Chapter 2
Materials and Methods
2.1 Animals and General Supplies
Long-Evans hooded rats were purchased from Charles River Breeding Farms in St.
Constant, Quebec. Superfrost slides were purchased initially from VWR (catalogue
number 48311-703) and recently from Fisher (catalogue number 12-550-18, 12-55016A); tissue embedding rings (catalogue number 25602-766) and paraffin (catalogue
number 72050-030) were purchased from VWR. Square glass Coplin jars with lids that
hold 10 slides were a gift from NRC Ottawa. Brain matrix for coronal sectioning for an
adult rat weighing between 300-600 g (catalogue number 15054) was purchased from
Ted Pella Inc. Disposable microtome blades (catalogue number DMB-LP) were
purchased from Triangle Biomedical Sciences. Antibody diluent (catalogue number
S0809) and blocking solution (catalogue number X0909) were purchased from DAKO.
Ultracruz mounting medium for fluorescence (catalogue number B2808) was purchased
from SantaCruz Biotechnology. Cytoseal™ 60 (catalogue number 8310-16) was obtained
from Richard-Allan scientific.
2.2 Stains, Kits and Antibodies
Hematoxylin mercury-free acidified solution (catalogue number 245-677) was
purchased from Fisher and Eosin Y alcoholic saturated solution (catalogue number 1502130) was purchased from VWR. Cresyl Violet acetate (catalogue number C1791) and
Diamino benzamidine (DAB) (catalogue number D8001-5G) were purchased from
Sigma. Luxol fast-blue and FD-Neurosilver kit (PK 301) were purchased from FD
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Neurotechnologies. Fluoro-jade B (catalogue number AG310) was bought from
Chemicon. Peroxidase substrate kit (catalogue number SK- 4100) was purchased from
Vector laboratories.
Primary antibodies: Rabbit anti-Tyrosine Hydroxylase polyclonal antibody
(catalogue number P40101-0) was purchased from Pelfreeze, and mouse anti-tyrosine
hydroxylase monoclonal antibody (catalogue number T2928) was bought from Sigma.
Rabbit anti-dopamine transporter polyclonal antibody (catalogue number AB1591P),
rabbit anti-vesicular monoamine transporter 2 c-terminus polyclonal antibody (catalogue
number AB1767), rabbit anti-glial fibrillary acidic protein polyclonal antibody (catalogue
number AB5804), rabbit anti-synuclein polyclonal antibody (catalogue number AB5038),
rabbit anti-parkin polyclonal antibody (catalogue number AB9244) and mouse anti-NeuN
clone 60 Alexa Fluor 488-tagged monoclonal antibody (catalogue number MAB377X)
were purchased from Chemicon. Rabbit anti-4-hydroxy nonenal polyclonal antibody
(catalogue number 393207) was purchased from

VWR. Rabbit anti-nitrotyrosine

polyclonal antibody (catalogue number A-21285) and Apo-brdU TUNEL assay kit
(catalogue number SKU#A23210) were purchased from Molecular Probes.
Secondary antibodies: Polyclonal goat anti-rabbit HRP conjugate (catalogue
number P0448) was purchased from DAKO; Anti-Rabbit IgG (whole molecule) FITC
antibody produced in sheep (catalogue number F7512) and anti-mouse IgG (whole
molecule) peroxidase conjugate (catalogue number A9044) were purchased from Sigma.

2.3 Reagents for Biochemical Assays
For Adenosine 5'-triphosphate (ATP) assay: lyophilized luciferin luciferase mix
(catalogue number FLAAM-1VL) was purchased from Sigma and ATP (catalogue
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number 93168322) was purchased from Roche. For reduced glutathione (GSH) assay:
GSH (catalogue number G-6529), Glutathione reductase (GSR) (catalogue number
G3664-500U) and DTNB (catalogue number D8130) were purchased from Sigma. The
proteome profiler rat cytokine array kit (catalogue number ARY008) was purchased from
R&D systems. For protein assays: Bovine serum albumin (BSA) (catalogue number
A7906) was purchased from Sigma and Bio-Rad protein dye assay reagent concentrate
(catalogue number 500-0006) was purchased from BIORAD. For lipid peroxidation
assay: tricholoro acetic acid (catalogue number T9159) and 2-thiobarbituric acid
(catalogue number T5500) and the MDA standard (1,1,3,3-tetramethoxypropane)
(catalogue number 108383) were purchased from Sigma. For SDS-PAGE and western
blotting: TEMED and bis-acrylamide were purchased from BIORAD; Tris-HCl, Glycine,
Tris-base and SDS were purchased from BD. Nitrocellulose membranes (catalogue
number 66485) were purchased from PALL Gelman Labs; low fat milk powder, Nestle
Carnation brand, was purchased from Canadian Tire. Chemiluminescent peroxidase
substrate (catalogue number CPS-160KT) was purchased from Sigma.

2.4 Water-soluble CoQio and Placebo
2.4.1 Water-soluble Formulation of Coenzyme Qi0 (WS-CoQio)
The WS-CoQio and placebo solution used in this experiment were supplied by
NRC Ottawa. The WS-CoQio was produced through a patented protocol (US patent #6
045 826) and contains both oxidized and reduced forms of CoQio in a 2: 1 (w/w) ratio.
Coenzyme Qio (CoQio) is contained within a water soluble "cage" made of polyethylene
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glycol and a-tocopherol (vitamin E). This water-soluble formulation was prepared from
C0Q10 (Kyowa Hakko, New York, NY) and polyoxyethanyl a-tocopheryl sebacate (PTS)
by directly combining both components in a molar ratio of 1: 2 mol/mol (1:3 w/w) and
heating them to a temperature higher than their respective melting points to form a clear
melt, which is water-soluble and can be diluted with aqueous solutions (e.g., phosphate
buffered saline (PBS), water, saline) to a desired concentration as previously described
(Borowy-Borowski et al. 2004) , (www.Zvmes.com).

2.4.2 PTS or Placebo
PTS/placebo was synthesized by conjugating polyethylene glycol 600 to atocopherol via bi-functional sebacic acid (Sigma-Aldrich, St. Louis, MO) as previously
described (Borowy-Borowski et al. 2004), (www.Zymes.com). Typically, stock solutions
of WS-CoQio (50 mg of CoQio and 150 mg of PTS per ml in PBS) or a placebo (150 mg
of PTS per ml of PBS) were made and stored at 4°C. These samples were then shipped to
Dr. Pandey at the University of Windsor. Stock solutions were diluted with regular
drinking water to a final concentration of 50 |ig WS-CoQio and 50 (ig PTS per ml
(placebo) for the experiments.

2.5 Instruments
A Genesys 10UV Spectrophotometer was used for measuring absorbance for
Bradford assays and lipid peroxidation assays. Centrifugation was performed using CR3i
Jouan centrifuge (fixed angle rotor: 13,000 r.p.m. (12520 xg) and swing bucket rotor:
38

4,000 r.p.m. (3023 xg)), DESAGA Starstedt-Gruppe centrifuge and Biofuge 15 centrifuge
from Baxter Scientific Inc. A SpectraMax GEMINI XPS from Molecular Devices was
used for luminescence (ATP assay) and fluorescent assays. The chemidoc from ALPHA
INNOTECH Corporation was used for gel imaging. Microscopes from MOTIC AE20
(attached to a Moticam 2300 camera, 3.0 MP Live resolution), Leica DM IRB, Nikon
ECLIPSE E800 (Dr. Zielinski's lab), ZIESS Axioskop 2 mot plus and (Dr. Crawford's
lab) were used for taking phase and fluorescent pictures. Microtomes from American
Optical Company (Dr. Crawford's lab) and MICROM HM 320 were used for sectioning.
Sorvall tissue grinder was used for homogenizing tissues. ELx808 IU Ultra microplate
reader from BIO-TEK INSTRUMENTS, Inc. was used for measuring absorbance in 96
well plates. Labconco freeze

dry system/freezone 4.5 lypholizer was used for

concentrating samples. Other general laboratory equipments used included the following:
A pH meter (Beckman, <E>310) with buffer solutions from ACP, an Adventurer™
balance and Scout ™ Pro balance (OHAUS), Vortex GVLab from Gilson(R) Industries
Inc., a 1296-002 DELFIAR plate shaker from Wallac, a Gibco BRL heatblock from
VWR, a Rocking platform model 200 from VWR, a Corning stirrer from Fisher
Scientific, a Sorvall OMNI-MIXER, a BIORAD Power Pac 200 and Eppendorf pipettes
from Fisher Scientific, VWR, and Gilson.

2.6 Animal Care
Twenty five male Long-Evans hooded rats (60-90 days old) were purchased from
Charles River, Quebec. Upon arrival, the rats were randomly split into two groups: those
that would receive injections of PQ and those that would receive injections of saline.
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These two groups were further divided into groups based on their water regimen: whether
they received WS-CoQio (50 (ig/mL), or placebo (50 jig/mL) in their drinking water or
plain drinking water. Throughout the experiment, developmental changes were made to
the model involving group division depending on water supplementation. The average
rate of water consumption for a rat is 10 ml per 100 g of body weight each day. At this
rate, an average sized rat (500 g) consumed 5 mg of either WS-CoQio or placebo per day.
Each one of the groups was housed in separate cages, which can hold between
four to five rats. During the weekdays, rats were placed in individual cages, fed 20 - 25 g
of rat chow, and given two hours to consume their meal. During the weekends, rats
remained in group cages and received group feedings. Plain water or water supplemented
with either WS-CoQio or placebo was available to the rats every day. On this feeding
schedule, the rats were kept at 90% of their normal, free-feeding weights verified through
weekly weighing. Given that rats are nocturnal, to ensure that they were awake during
the day for behavioural testing, the rats were kept on a reversed 12 h: 12 h light: dark
cycle with the temperature maintained at 20°C. All animal care, treatments, and
procedures were approved by the University of Windsor's Animal Care Committee
(AVPP060010706) in accordance with the Canadian Council for Animal Care guidelines.
Please refer to Appendix A for further details on injecting animals.

2.7 Injection Regimes
2.7.1 Three Injections of PQ
Two different experimental designs were used for the three injection study.
Figure 2.1 describes the time-line and group allocation for both experiments. Previous
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studies have used three intraperitoneal injections of PQ (10 mg/kg) to induce selective
damage to dopaminergic neurons in the SN in mice; we used a similar protocol in rats
(McCormack et ah 2002).
Experiment #1: Sixteen naive adult male Long-Evans hooded rats were used in
the first experiment, designed to establish the regimen of PQ-injections, the degree of
neurodegeneration and potential neuroprotection by WS-CoQi0. Figure 2.1A outlines the
procedures applied in this experiment: three weeks prior to the first saline or PQ injection
(and for the duration of the experiment) the rats received either plain water or water
supplemented with WS-CoQio or placebo. The rats were given three weekly
intraperitoneal injections of PQ (10 mg/kg body weight dissolved in saline) or saline. The
rats were further divided according to the treatments they received: one group received
saline injections and plain water; a second group received PQ injections and plain water;
a third group received PQ injections and drinking water supplemented with placebo and
the fourth group received PQ injections and WSCoQio supplemented drinking water
(Figure 2.1A). Since placebo (PTS) is a pro-drug form of vitamin E (in which tocopherol
was chemically derivatised by sebacic acid and PEG) that is used as a component
(carrier) of the WS-CoQio formulation (Sikorska et ah 2003), the effect of WS-CoQio
was compared to placebo and water treated groups. Rats were sacrificed one week after
the last injection and the brains from these rats were extracted, fixed in formaldehyde.
This experiment was repeated with sixteen rats. For this set of rats, biochemical
parameters were performed for 2 rats from each group.
Experiment #2: Twenty-five naive adult male Long-Evans hooded rats were used
for this experiment and were exposed to a similar injection schedule as in Experiment 1.
The PQ-induced neurodegenerative and WS-CoQio neuroprotective effects that resulted
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from Experiment 1 prompted us to conduct a second experiment (Figure 2.IB) which is
modified not only to assay histological/biochemical parameters of PQ-induced
neurodegeneration, but also to determine PD-like behavioural changes from such
exposure and to determine whether WS-CoQio treatment could prevent PQ-induced
behavioural impairment. Due to the fact that no significant differences in nigral neuronal
counts were observed between the PQ-Placebo and PQ-Water treatment groups in
Experiment 1, we eliminated plain water treatment from Experiment 2, and gave the rats
either WS-CoQio or its carrier solution (Placebo) in the drinking water. Thirteen rats that
received drinking water supplemented with WS-CoQio and were divided into two
injection groups: Saline-CoQio (n=6) and PQ-CoQio (n=7). Twelve rats that received
placebo supplemented drinking water were divided into two groups based on the injection
regime: Saline-Placebo group (contained six rats) and the PQ-Placebo group (contained
six rats). Rats were sacrificed two weeks after their last injection as opposed to one week
in experiment 1. This additional week allowed us to carry out post-injection behavioural
assessment of gait performance on the rotorod apparatus. Three rats from each group
were used for staining and three were used for biochemistry experiments.
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Figure 2.1 Schematic outlines for the three injection PQ regime. (A) Experiment
1scheme. (B) Experiment 2 scheme.
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2.7.2 Five Injections of PQ
Since eight injections proved to be very toxic to rats, we decided to see if five
injections of PQ would achieve a greater neuronal loss than the three injection regime.
After arrival, rats were randomly grouped and subjected to three weeks of behavioural
testing to establish a baseline of their motor abilities (Figure 2.2). Following this, the rats
were injected once a week for five weeks giving a total of five injections. After
conducting the post injection behavioural studies the rats were dissected and tissues were
collected for various experiments. This regime was followed for two sets of experiments:
One to study the prophylactic versus therapeutic effects of WS-C0Q10 and two, to
compare the effects of PQ between old and young rats.
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Figure 2.2 Timeline for five injection regime.
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2.7.2.1 Prophylactic vs. Therapeutic Effects of WS-C0Q10
In order to study the effects of various neuroprotective agents, they are either
administered before inducing the disease condition (prophylactic use) or after inducing
the disease condition (therapeutic). To design an experiment to study the prophylactic and
therapeutic effects of WS-C0Q10, 24 naive rats were divided into six groups. One group
received intraperitoneal injections of saline. The other five groups received
intraperitoneal injections of PQ (10 mg/kg). After the fifth injection, the drinking water
for two of the five PQ-injected groups was changed in order to investigate the effects of
WS-CoQIO administered after PQ-induced neurodegeneration. One of the two groups
received WS-CoQIO supplemented water, starting immediately after the last injection
(the next day), while the other received placebo (Table 1). The drinking solutions were
prepared the same for all experiments. The behavioural assessments continued throughout
the experiment to obtain post-injection measurements. Three weeks after the last
injection, two rats from each group were sacrificed for biochemical analyses and two
from each group were processed for histochemistry. This experiment was repeated with
the same number of rats, groupings and water supplementation.

Table 1. WS-CoQio feeding regime prior to and after injections of PQ.

1
2
3
4
5
6

4
4
4
4
4
5

Saline
PQ
PQ
PQ
PQ
PQ

Water
Water
Placebo
WS-CoQio
Water
Water
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Unchanged
Placebo
CoQio

2.7.2.2 Old vs. Young Rats
This experiment was designed to compare the effects of PQ-induced
neurodegeneration in young versus old rats as well as to evaluate the neuroprotective
effects of WS-C0Q10. Sixteen naive young rats (purchased between 60-90 days old) and
16 old rats (purchased between 300-350 days old). The young and old rats were divided
into four groups on the basis of injection and water regime (Table 2). The behavioural
assessments continued in the pre-, mid- and post-injection phases. Two rats from each
group were processed for histochemistry while the other two were used for performing
biochemical analyses. This study is yet to be repeated.

Table 2. Grouping young and old rats on the basis of injections and water regimen.

1
2
3
4
5
6
7
8

4
4
4
4
4
4
4
4

Saline
PQ
PQ
PQ
PQ
PQ
Saline
PQ

Water
Water
WS- CoQio
Placebo
Water
WS- CoQio
Water
Placebo
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Young
Young
Young
Young
Old
Old
Old
Old

2.8 Tissue Harvesting for Brain Histochemistry
The rats were placed into a plexi-glass chamber and anaesthetized with isoflurane
until the rat was unresponsive to a noxious stimulus (i.e., pinched leg). Following this, an
anaesthetic muzzle was placed on the rat and the rat was then transferred onto a
dissection tray. An incision was made from the pelvis to the neck and both the pleural
and thoracic cavities were opened. To perfuse the rat, a 12 gauge needle was inserted
into the left ventricle of the heart. Tyrodes solution (B.76 g NaCl, 0.298 g KC1, 0.222 g
CaCl2, 2.603 g HEPES, 1 g dextrose, 1 g NaHC03, 0.06 g Na2HP04*4H20 per litre)
containing 1 U/ml heparin to prevent blood clotting, was gravity fed through the twelve
gauge needle (Cassella et al. 1997). Once a noticeable discoloration of the liver was
observed, the Tyrodes solution was exchanged for a PBS (8 g NaCl, 0.2 g KC1, 2.68 g
Na2HP04-7H20 and 0.24 g KH2P04 in 800 ml water, pH=7.4) containing 10%
formaldehyde. This perfusion which used 10% buffered formaldehyde was continued
until a noticeable rigidity developed in the muscles of the rat. Following this, the lungs,
heart, kidney, liver, spleen and brain of the rat were harvested and placed in 10%
buffered formaldehyde for 24 hours at 4°C to fix the tissues. Following fixation the
tissues were transferred to 70% ethanol and stored at 4°C. Please refer to Appendix B for
further details.
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2.9 Tissue and Slide Preparation
2.9.1 Brain
After harvesting and fixing the tissues, a 4 mm thick coronal section was cut out
of the midbrain using a brain matrix for coronal sectioning for an adult rat. To prepare the
brain tissue for slicing on the microtome, it was dehydrated and embedded in paraffin
wax as described below.
After removal from 70% ethanol, the brain tissue was moved through dehydrating
solutions: 95% ethanol for 60 minutes; 100% ethanol for 60 minutes; Xylene for 30-45
minutes; 50/50 (v/v) mixture of Xylene and paraffin wax for 45 minutes at 60°C; and
finally 100% paraffin wax overnight at 60°C in a water bath. Please refer to Appendix D
for more details.
Once the tissues were embedded in paraffin, they were placed into metal moulds
and left to cool for approximately three hours at room temperature. Coronal sections, 8
jim thick, were cut across the entire SN region and processed for immunohistochemistry
using a stereotaxic rat brain atlas. The sections were placed on slides and dried overnight
in an incubator at 40°C.

2.9.2 Peripheral Organs

Dehydration and paraffin embedding of the peripheral organs was performed
using the protocol as mentioned in Section 2.8.1. Using a microtome, 8 |xm sections were
taken for immunohistochemical analysis.
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2.10 Preparation and Staining for Immunohistochemistry of the Brain Tissues
2.10.1 Using 3,3'-diaminobenzidine (DAB)
Our DAB staining procedure was slightly modified from a previously used
protocol. To begin immunohistochemistry, the tissues on slides were subjected to
deparaffinization and rehydration. To deparaffinize, these slides were incubated in xylene
for 20 minutes (2 x 10 minutes). To rehydrate, the slides were then incubated in 100%
ethanol for 10 minutes; 95% ethanol for 10 minutes; 70% ethanol for 5 minutes;
immersed in 50% ethanol; immersed in 30% ethanol; immersed in dH20; and incubated
in 50 mM TBS (50 mM Tris-HCl, 150 mM NaCl, pH=7.6) for 5 minutes. The slides
were then incubated for 30 minutes in methanol containing 3% H2O2 to block endogenous
peroxidase activity of the tissue. The slides were then processed for antigen retrieval by
incubation in 1 mM EDTA pH=8.0 heated to 95°C in a water bath for 20 minutes and
then cooled for 20 minutes at room temperature. Finally, the slides were washed for 5
minutes in 50 mM TBS, washed for 5 minutes in distilled water and incubated for 15
minutes at room temperature with a universal blocking solution. Excess solution was
removed and the slides were subjected to the primary antibody of interest in a humid
chamber overnight at 2-8°C. The slides were then washed with TBS for 15 minutes (3x5
minutes) and were subjected to the appropriate secondary antibody for 1 hour at room
temperature and again washed in TBS for 15 minutes (3x5 minutes). Negative controls
included the omission of primary or secondary antibodies.
Immunolabelling

was

accomplished

by

using

0.02% diaminobenzidine

tetrachloride and 0.006% H2O2 for 10 minutes at room temperature. Sections were
washed in running water and counterstained with Mayer's hematoxylin for 90 seconds.
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The slides were washed in TBS for 5 minutes to remove excess stain, and then immersed
in a 0.2% HC1 in ethanol destaining solution followed by 10 dips in 10% NH4OH. The
tissue was then dehydrated in 95% ethanol for 10 minutes; 100% ethanol for 10 minutes;
and xylene for 10 minutes (2x5 minutes). The slide was then sealed with cytoseal and a
cover slip.

2.10.1.1 Tyrosine Hydroxylase (TH) Staining using DAB
For the three injection regime, neurons were counted using DAB staining.
Staining for TH using DAB began with the same steps as outlined in section 2.10.1.
After blocking the slide for 15 minutes with blocking solution, the brain sections were
incubated with rabbit polyclonal anti-tyrosine hydroxylase antibody (1:500, using DAKO
antibody diluent) overnight at 4°C. These slides were washed in TBS for 15 minutes (3 x
5 minutes), and then incubated for 1 hour at room temperature with goat anti-rabbit IgG
peroxidase conjugated secondary antibody. The rest of the protocol was followed as
outlined in 2.10.1.
Loss of dopaminergic neurons (three injection regime) was determined by
counting TH-immunopositive cells (cell body) under bright-field illumination. Sections
were taken across the SN (bregma -5.04 mm to bregma -6.24mm) and stained for THimmunopositive neurons. The region for counting was delineated using a stereotaxic rat
brain atlas. After delineation of the SNc using 10X objective, TH-immunopositive
neurons were counted manually at different levels. The mean numbers of THimmunopositive neurons per section were calculated for each level. Analysis of the three
injection regime was performed as a blind study where neurons were counted manually
by two people.
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2.10.1.2 Glial Fibrillary Acidic Protein (GFAP) Staining using DAB
Staining for GFAP was performed by using a DAB-based detection protocol.
Brain sections were incubated with rabbit polyclonal anti-GFAP (1:500, DAKO
Cytomation Inc.) overnight at 2-8°C. Slides were washed (refer to 2.10.1) and the
sections were subjected to secondary antibody conjugated to goat anti-rabbit IgG (1:500)
for 60 minutes at room temperature. Immunolabelling was detected using DAB according
to the protocol described in 2.10.1. This procedure is used by our collaborators at NRC
Ottawa.

2.10.2 Using Immunofluorescence
A modified version of a previously published protocol was used (Thiruchelvam et
al. 2000b). Briefly, tissue sections were deparaffinized in xylene for 20 minutes; 100%
ethanol for 10 minutes; and incubated in TBS as described above. Non-specific IgGs
were blocked with DAKO universal blocking solution for 15 minutes at room
temperature. Excess liquid was removed and sections were incubated with primary
antibody overnight in a humid chamber at 2-8°C and then washed with TBS as described
above. Tissues were incubated with the appropriate secondary antibody tagged to
fluorescein isothiocyanate (FITC) for 1 hour at room temperature and then washed for 15
minutes in TBST and dehydrated in 95% ethanol for 10 minutes, followed by 100%
ethanol for 10 minutes and then xylene incubation for 10 minutes (2x5 minutes). The
slides were mounted with mounting media containing DAPI and the cover slips were
sealed with clear fingernail polish. The slides were stored at -20°C.
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2.10.2.1 Tyrosine Hydroxylase (TH) Staining with Fluorescence
For the five injection regime, neurons were counted using immunofluorescence
staining. Staining for TH began with the same steps as outlined in 2.10.2. After blocking
the slides for 15 minutes with blocking solution, the brain sections were incubated with
rabbit polyclonal anti-tyrosine hydroxylase antibody (1:500, using DAKO antibody
diluent) overnight at 2-8°C. These slides were then washed in 50 mM TBS for 15
minutes (3x5 minutes) and then incubated for 1 hour at room temperature with antirabbit FITC conjugated secondary antibody (1:200 using DAKO antibody diluent). Next,
the slides were washed for 15 minutes (3x5 minutes) in 50 mM TBS, mounted with
mounting media containing DAPI and cover slips were sealed with clear fingernail
polish. All slides were then stored at -20°C. Images were captured Nikon ECLIPSE
E800, ZEISS Axioskop 2 Mot Plus or Leica DM IRB microscopes.
For the analysis of the five injection regime, the SNc neurons were counted
manually by two people: one person was familiar to the groups while the other was not.
In this pilot study, evaluating the Prophylactic vs. Therapeutic effects of WS-CoQio,
neurons were counted from two rats per group while in the five injection regime studying
the effects of aging (Old vs. Young), neurons were counted from one rat per group. Every
sixth section across the entire SNc was counted (both the left and the right sides) to
obtain TH-immunopositive neuronal numbers.

2.10.2.2 Glial Fibrillary Acidic Protein (GFAP) Staining with Fluorescence
Staining for GFAP began with the same steps as outlined in 2.10.2. After blocking
the slide for 15 minutes with blocking solution, the brain sections were incubated with
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rabbit, monoclonal anti-GFAP antibody (1:500, using DAKO antibody diluent) overnight
at 2-8°C. These slides were then washed in 50 mM TBS for 15 minutes (3X5 minutes)
and then incubated for 1 hour at room temperature with anti-rabbit FITC conjugated
secondary antibody (1:200, using DAKO antibody diluent). The slides were then washed
for 15 minutes (3x5 minutes) in 50 mM TBS and then mounted with mounting media
containing DAPI; the sides of the cover slip were sealed with clear fingernail polish. All
slides were then stored at -20°C until before and after photography. For counting
activated astrocytes, no particular parameters were set for this batch of experiments.
However, it is recommended to set parameters that define activated conditions of
Astrocytes.

2.10.2.3 NeuN (neuronal nuclei) staining
Staining for NeuN began with the same steps as outlined in 2.10.2. The
manufacturer's protocol (Chemicon) was followed for antigen retrieval and antibody
dilution. After incubation in 50 mM TBS for 15 minutes the sections were subjected to
antigen retrieval using fresh lOmM sodium citrate (pH=6.0) for 20 minutes at 90°C in a
water bath. Following this sections were allowed to cool down to room temperature for
30 minutes. Next, the sections were washed with 50 mM TBS for 5 minutes and
incubated with DAKO universal blocking solution for 15 minutes in a humid chamber at
room temperature. Excess blocking solution was removed and slides were incubated with
NeuN antibody (1:100, using antibody diluent) overnight at 2-8°C. The slides were then
washed with 50 mM TBS and dehydrated, incubated with xylene and cover slipped using
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mounting media containing DAPI and sealed with clear fingernail polish. All slides were
then stored in -20°C.

2.10.3 Hematoxylin and Eosin (H&E) Staining for Brain and Peripheral
Histopathology
The protocol was modified slightly from the original version obtained from NRC,
Ottawa. The same protocol was used for staining the brain and peripheral tissues (lung,
liver and kidney). Slides were subjected deparaffinization in xylene for 20 minutes (10 x
2 minutes), rehydration in 100% ethanol for 10 minutes, 95% ethanol for 5 minutes, 70%
ethanol for 5 minutes and dH^O for 5 minutes. The slides were stained with hematoxylin
for 3 minutes, and washed in dl^O for 5 minutes. They were then immersed twice in acid
alcohol (0.2 mL HC1 in 100 mL 70% ethanol) and rinsed with running water and dH^O.
Slides were then incubated for about 1 minute in eosin, rinsed and washed in 95%
ethanol, followed by 100% ethanol for 10 minutes each and finally immersed in xylene
for 20 minutes (2x10 minutes). The slides were cover slipped using cytoseal mounting
media.

2.11 Tissue Fractionation of the Brain
The rats designated for biochemical analysis (after completion of behavioural
studies) were sacrificed by CO2 inhalation in accordance with a protocol approved by the
Canadian Council for Animal Care. Briefly, isolated brains were washed with ice-cold
PBS and placed on ice until further dissection. For the three injection regimes, the brain
was further dissected into the frontal cortex, the midbrain and the striatum. Rats were
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sacrificed and experiments were done on the same day. Therefore, fresh midbrain and
striatum homogenates were used for the three injection assays. The tissues were weighed
and homogenized in 10 volumes (10 ml buffer for lg tissue) of ice-cold homogenization
buffer (50 mM Tris-HCl, 0.15 mM NaCl, 10 mM EDTA, 1% TritonX-100, 1 mM PMSF,
1 |J.g/ml pepstatin A, 1 jig/ml leupeptin, pH=7.5) (Akita et al. 2001). The homogenates
were centrifiiged for 10 minutes at 3,000 r.p.m using a Jouan CR3i centrifuge and a T40
swing bucket rotor at 4°C. The nuclear pellet (and debris) was discarded and the
cytoplasmic/cytosolic fraction (supernatant) was used for GSH analysis, lipid
peroxidation, cytokine array and Westernblots. Half of this supernatant (obtained after
centrifugation at 3000xg) was subjected to centrifugation again at 12,520 xg to separate
the mitochondrial fractions that were used for ATP assay.
Unless utilised immediately, the cytoplasmic fractions were frozen at -80°C in
250 fj.1 aliquots. If the assay was performed on frozen lysate, then the lysate was subjected
to centrifugation at 3000 r.p.m for 7-10 minutes at 4°C and the pellet was discarded,
prior to being assayed.
For the five injection regime, there was a slight modification after the dissection.
Instead of utilizing the midbrain and the striatum, only the midbrain was utilized for all
assays in this regime. Furthermore, instead of utilizing fresh homogenates, the midbrain
tissues were snap frozen in liquid nitrogen and stored at -80°C in this regime, (refer to
Appendix C). Later these tissue homogenates were prepared and cytoplasmic fractions
were obtained as mentioned above. All the assays: GSH, lipid peroxidation, ATP,
Western blots, Cytokine analysis were performed on cytoplasmic fractions. Please refer
to the summary Table 4 at the end of this chapter.
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2.12 Protein Estimation Using Bradford Assay
The concentration of proteins present in the tissue homogenates was estimated
using the protocol from BioRad Laboratories. The protein estimation was performed in
duplicates by using 2 juil of each sample, 798 nl of dHhO and 200 jil of BioRad protein
assay reagent to a total volume of 1 ml in plastic cuvettes. The mixtures were then
vortexed and allowed to stand for 5 minutes at room temperature. The absorbance was
then measured by using a Genesys UV-Visible Spectrophotometer at 595 nm. The
standard curve was prepared by using 1 to 14 fxl of lmg/ml Bovine serum albumin (BSA)
standard, 799 to 786 p.1 of dt^O and 200 jil of BioRad protein assay reagent. Graph Pad
Prism software was used for data representation.

2.13 Glutathione (GSH) Assay
The GSH assay was performed using a slight modification of a previously
published method (Baker et al. 1990). Briefly, 2 jal of the homogenate and 100 |il of
reaction mixture (containing 1 mM NADPH and 100 units GSH reductase in distilled
water) was added in a 96-well plate and then incubated for 20 minutes at 37°C. Following
incubation, 100^1 of 1 mM DTNB (dissolved in 0.1 M PO4 buffer, pH=8.0) was
incubated for 15 min at 37°C. Absorbance was measured at 412 nm using a Bio-tek ELx
808ru Ultra Micro plate Reader. GSH levels were determined from the standard curve
constructed by using 1 mM GSH. Results were expressed per microgram of protein.
Protein concentration was measured using the BioRad protein assay reagent and bovine
serum albumin was used as a standard as above. Graph Pad Prism software was used for
data representation.
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2.14 Lipid Peroxidation Assay
The lipid peroxidation assay was performed as previously described (Cereser et
al. 2001). Briefly, 100 |xl of the homogenate obtained from the midbrain was added to
lml of thiobarbituric acid (7 g trichloroacetic acid, 0.185 g thiobarbituric acid, 12.5 ml
0.25 N HCl in 37.5 ml dF^O) and incubated at 100°C on a heat block for 20 min. After
cooling the tubes, absorbance was measured at 535 nm using a Genesys
spectrophotometer. Lipid peroxidation levels were determined from a standard curve
prepared using 100 juiM malondialdehyde (MDA). Results were calculated per microgram
of protein. Protein concentration was measured using the BioRad protein assay reagent
with bovine serum albumin as a standard. Graph Pad Prism software was used for data
representation.

2.15 ATP Assay
ATP content was measured as previously described (Sandhu et al. 2003). Briefly,
100 |nl of tissue homogenate was mixed with 100 (il luciferin-luciferase solution in a
black 96-well plate and incubated for 30 minutes at 37°C and the bioluminescence was
using a plate reader using a Spectra Max Gemini XS spectrophotometer at 560 nm. The
amount of ATP produced was determined from internal standard curve prepared by using
100 pM ATP standard solution. The final results were expressed per microgram protein.
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2.16 SDS-PAGE and Western Blotting
The SDS-PAGE and western blot protocols were slightly modified from the
original protocol (Sambrook et al. 1989). All the western blots were conducted used the
following protocol with variations in the primary and secondary antibody as needed
[monoclonal anti-TH (1:1000), polyclonal anti-GFAP (1:1000), polyclonal anti-PARKIN
(1:1000), or polyclonal anti-synuclein (1;1000), polyclonal anti-iNOS (1:500)]. Protein
samples were resolved using a 10% SDS-PAGE. 20 jig of protein (per well) was mixed
with 4 X loading buffer (50 mM Tris-HCl, pH=6.8, 100 mM dithiothreitol, 2% SDS,
0.1% bromophenol blue and 10% glycerol), heated for 2 minutes on a heat block at 95°C
and then centrifuged before being loaded onto the gel. The protein was transferred from
the gel onto a nitrocellulose membrane which was subsequently blocked using a non-fat
5% milk solution in TBS with 0.2% Tween (TBST) for 1 hour on a shaker at room
temperature. Then blots were then stained with Ponceau S and the blots were scanned and
recorded to ensure equal loading. The membrane was then incubated with the required
primary antibody in 2% non-fat milk solution overnight at 4°C for 12-18hours. After this
incubation period, the membrane was washed with TBST for 15 minutes, followed by
three more five minute washes and finally incubated with secondary antibody (antimouse IgG (whole molecule) or anti-rabbit (whole molecule) peroxidase conjugate) at a
dilution of 1:3000 in 2% milk solution and incubated at room temperature on a shaker for
Ih. Finally, the blots were then washed with TBST for 30 minutes (1x15 minutes, 3x5
minutes) and developed using a ChemiGlow West kit according to manufacturer's
protocol (Sigma Aldrich) and recorded using an Alpha Innotech Corporation Imaging
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System. All the Western Blots were performed twice from tissue homogenates obtained
from one animal in each group.

2.17 Cytokine Array
In order to assess the relative levels of multiple cytokines in rats undergoing
various treatments, a cytokine assay was performed. Tissue homogenates were prepared
according to a protocol provided with the kit from R&D Systems. Briefly, the mid brain
was homogenized in PBS (pH=7.6) with protease inhibitors (1 (iM leupeptin, 1 |jM
pepstatin A and 10 (iM PMSF) and 0.1% Triton-X-100. The samples (100 fig protein)
were incubated with detection antibody cocktail for 1 hour at room temperature on a
rocking platform. Meanwhile, the membranes were incubated with blocking solution for
1 hour at room temperature, after which the sample/detection antibody mixture was
applied onto the membranes and they were incubated on a rocking platform overnight at
2-8°C. The membranes were washed with Wash buffer for 30 minutes (3x10 minutes).
After blotting excess wash buffer the membranes were incubated with Streptavidin-HRP
and incubated for 30 minutes. The membranes were then washed for 30 minutes and
incubated with chemiluminescent reagent in accordance with the manufacturer's
protocol. The images were recorded with an Alpha Innotech Corporation Imaging
System. Data was obtained from two rats in each group belonging to the five injection
regime.
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2.18 Behavioural Assessment
2.18.1 Rotorod Apparatus
We measured rats' ability to maintain their balance on a rotorod as per a
previously described protocol (Winer, 1978). This rotorod apparatus consisted of a papercovered (80 grid) 15 cm long, 7 cm diameter wooden dowel attached to a variable speed
motor. Clockwise revolutions of the rotorod could be adjusted from 6 to 12 R.P.M. The
rod was separated from the motor by a vertical 30 x 48 cm grey wooden panel that was
scored with black vertical and horizontal lines to form 12 x 12 cm squares as shown in
Figure 3.7B. The apparatus rested on a small table so that the dowel was 27 cm above its
surface. A digital video camera (Orbyx Electronics Inc, CA) was positioned 1 m in front
of and level with the rod. The apparatus was illuminated by regular fluorescent ceiling
lighting and a 60-W lamp approximately 3 m in front of it.
Experiment 2 setup consisted of a two week pre-injection phase followed by an
injection phase of three weeks and a two-week post-injection phase. Rats received three
rotorod sessions during the pre-injection phase, spaced approximately two days apart
over the two-week period, one rotorod session five days after the second injection (midinjection test), and one session in the post-injection phase given one week after their last
injection. The first two pre-injection sessions served to train the rats to maintain their
balance on the rotorod and gradually its rotation speed from 6 to 12 R.P.M was increased.
From the third test on, the rotorod's rotation speed was maintained at 12 R.P.M. Rats'
performance on the third pre-injection test provided baseline performance for comparison
with the next two tests. Rats were always placed in the forward position (facing left) as
the rod rotated clock-wise.
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2.18.2 Dependent Behavioural Measures and Statistical Analyses
Each rat's video recording was converted to 5 frames per second still pictures
from which we recorded its movements over the last 100 seconds (500 frames) with a
software tracking program (7 Software, Inc, Montana, U.S.A.). Figure 3.7B illustrates a
picture frame superimposed on the tracking frame composed of 450 vertical and 450
horizontal pixels. It was noted that although rats were initially oriented to walk forward
on the slowly rotating rotorod, they also turned around and walked backward during
some portions of these sessions. Therefore, we calculated the amount of time each rat
actually spent (proportion of frames) walking backward as well as its average horizontal
and vertical nose locations as it walked in each direction.
Each rat's proportion of time spent walking backward was transformed into an
arcs in 2^X measure to enhance homogeneity of variance for parametric statistical
analysis of proportion scores (Whishaw et al. 2003). Each dependent measure was
analyzed by 2 (Injection: PQ vs. Saline) by 2 (Liquid Supplement: CoQio vs. Placebo) by
3 (Rotorod Test Session: pre-, mid-, post-injection) analysis of variance (ANOVA) with
repeated measures on the last factor. We conducted statistical analyses of the behavioural
data with SPSS (version 17) program and report significant effects at p <0.05.

2.19 Statistical Analysis
Unless otherwise stated, all the biochemical data are represented as the mean ±
SEM of three independent animals; each assayed in triplicate. For the statistical analysis
of the histochemical data, three animals have been used unless stated otherwise. A value
of P<0.05 is considered as statistically significant. Two way ANOVA tests followed by
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post-hoc Bonferroni's multiple comparisons test was used to assess statistical differences
were performed using S.P.S.S software version 17 for three injection regime of PQ. Since
the five injection studies were preliminary, no ANOVA was performed.
T-tests were performed using Statistica 7.0 software for all the in vitro studies.

2.20 Experiments Designed to Study the Mechanism of Neuroprotection by WSCoQio
2.20.1 Cell Culture
2.20.1.1 Human Neuroblastoma Cells or (SH-SY5Y cells)
SH-SY5Y cells were grown as per manufacturer's protocol (ATCC) in Ham's F12
medium (Gibco) with 2 mM L-Glutamine that was modified to contain 1.5 g/L sodium
carbonate, 10% Fetal Bovine Serum and 10 mg/ml gentamycin at 37°C at 5% CO2. The
cells were sub cultured by splitting 1:5 once a week.
2.20.1.2 Transformed Human Embryonic Kidney Cells (HEK 293 cells)

Cells were grown according to manufacturer's protocol (ATCC) using DMEM/F12 media (Sigma). The media were supplemented with 15% (v/v) Fetal Bovine Serum
(FBS) in tissue culture flasks and/or Petri dishes and incubated in 5% CO2 at 37°C and
95% humidity.
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2.20.2 Measurement of ROS Production from Isolated Mitochondria of SHSY-5Y
cells and HEK 293 cells

SH-SY5Y cells were grown, and intact mitochondria were isolated as previously
described (Li et al. 2003). Cells were harvested by mechanical dislodging using a rubber
policeman and centrifuged at 500 x g for 5 minutes. They were washed twice with ice
cold PBS and centrifuged at 250 x g, the cells were re suspended in isolation buffer
containing 1 mM EDTA, 10 mM HEPES (pH= 7.4) and 250 mM sucrose. Cells were
homogenized by a Dounce homogenizer with 20 strokes. The disrupted cells were
centrifuged for 5 minutes at 600 x g at 4°C. The supernatant was collected and
centrifuged at 15,000 x g at 4°C for 5 minutes and the resulting pellet was mitochondria.
The pellet was re-suspended in buffer without EDTA. Mitochondrial suspensions were
kept on ice and all the experiments were performed within 5 hours. For rotenone or PQinduced mitochondrial dysfunction, mitochondrial hydrogen peroxide was measured
using p-hydroxy phenyl acetic acid (PHPA) by an increase in the fluorescence due to
oxidized p-hydroxyphenylacetate fluorescence by horseradish peroxidase as previously
described (Li et al. 2003). Total mitochondrial protein was estimated using BioRad with
BSA as a standard. The reaction began by adding 50 |ig of mitochondria to a 100 )il
reaction mixture containing 0.25 M Sucrose,10 mM HEPES 10 ng/ml PHPA and 0.4
units of HRP per well. In order to study the effects of WS-CoQio, 50 ng/ml CoQio was
incubated with mitochondria for 30 minutes prior to addition of 10 |iM rotenone, or 200
|j,M PQ. 10 mM succinate was added as a substrate and the contents were mixed. After 30
minutes of incubation, the fluorescence of oxidized PHPA (excitation 320 nm, emission
400 nm) was measured in a 96 well micro-titer plate using the Spectra Max Gemini XS.
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Graph Pad prism 4.0 was used for data representation. This experiment was done in
triplicate and repeated three times.
For Bax-induced mitochondrial dysfunction, mitochondria were isolated from
HEK 293 cells. The mitochondrial pellet, isolated as described above, was re-suspended
in a reaction buffer consisting of 0.25 M sucrose, 1 mM MgCh, 10 mM HEPES, 100 mM
succinate and 10 mg/mL PHP A. Mitochondria, were either untreated or pre-treated for 30
min with 0.5 mg/mL WS-CoQio formulation. Following the 30 minute incubation with
WS-CoQio, they were incubated with 5 (xg/mL of recombinant Bax for 5 minutes at room
temperature. Control mitochondria were not treated with Bax. The mitochondrial
suspensions (100 \iL per well) were placed in a 96 well plate and the wells were
subsequently treated with 0.4 units of HRP and fluorescence was measured starting
immediately after the addition of HRP for 10 min in 30-s intervals. The fluorescence
readings were performed using the Spectra Max Gemini XS at an excitation wavelength
of 320 nm and an emission wavelength of 400 nm. Microsoft excel was used for data
representation. This experiment was done in triplicates and repeated thrice.
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Table 3. Summary of immunohistochemistry experiments during different injection
regimes.

mi
Number of
rats
(per group)

3

2

1

2

Type of
Staining

DAB

DAB & IF

IF

DAB &IF

Stained for

TH

TH, GFAP & NeuN

TH

TH, GFAP,
Parkin, VMAT,
4-HNE & asynuclein

Table 4. Summary of the biochemical assays performed during different injection
regimes.

IHI
Brain
Region
Assayed
Type of
tissue used
Type of
Assay

Midbrain & Striatum

Midbrain

Midbrain

Fresh

Frozen

Frozen

GSH, mitochondrial
and total ATP, Lipid
Peroxidation

GSH, total ATP & Lipid
Peroxidation

GSH
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Chapter 3
Results
This chapter is divided into three parts. The first part of the chapter focuses the
results obtained from the initial studies with three injections of paraquat. The second part
focuses on the specificity of paraquat treatment and evaluation of neuroprotection offered
by WS-C0Q10 at higher doses of paraquat. The final segment focuses on deciphering the
probable mechanism of neuroprotection offered by WS-CoQio-

3.1. Initial Studies with Three Injections of Paraquat
This study was performed to evaluate:
1. The toxicity of paraquat to the dopaminergic neurons.
2. Neuroprotection offered by WS-CoQio against paraquat mediated toxicity.

3.1.1. Effects of PQ on DA Neurons in the Midbrain and Neuroprotection by WSCoQio
Many studies have used tyrosine hydroxylase (TH) immunostaining to estimate
the number of dopaminergic neurons (McCormack et al. 2002, Peng et al. 2007). TH is
an enzyme which converts the amino acid tyrosine into dihydroxyphenylalanine (DOPA).
This reaction is the first step in the production of dopamine (Figure 3.1).
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Norepinephrine
Tyrosine

TH

DOPA

Dopamine
Epinephrine

Figure 3.1 Conversion of tyrosine to dopamine. Tyrosine is converted to DOPA by
tyrosine hydroxylase (TH), which is the rate limiting enzyme.

TH-immunostaining is used as a marker of choice since TH is the limiting enzyme
for dopamine synthesis and is clearly reduced after dopaminergic insults (Emborg 2004).
Examination of midbrain sections revealed a reduced TH-immunostaining in the
PQ-injected rats (for Water-fed and Placebo-fed groups, Figure 3.2B and 3.2C
respectively) as compared to the control Saline-injected rats (Figure 3.2A). There also
was diminished staining of TH-positive fibres, indicating neuronal loss and reduced fibre
density (compare Figures 3.2B-b'and 3.2C-c' to 3.2A-a').
In contrast, the images of the PQ-WS-C0Q10 midbrain sections showed strong
TH-immunostaining of both the cell bodies and the fibres (Figure 3.2D and 3.2D-d').
This group of rats was given the WS-C0Q10 supplemented drinking water, which might
have counteracted the effects of PQ. The immunostaining data was confirmed by
counting the TH-immunopositive neurons in the entire SN region (Figure 3.2E).
The counts revealed approximately 60% reduction of the number of cells in the
PQ-injected rats receiving regular drinking water (from 313.7 ± 6.4 in the saline group to
91.3 ± 3.4 in the PQ-Placebo group, P<0.001) and about 60% reduction in the placebo
fed group (down to 143.7 ± 4.3) compared to saline injected group. The cell counts also
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confirmed the neuroprotective effects of WS-C0Q10. Although the approximate number
of TH-immunopositive neurons in the PQ-WS-C0Q10 group was lower than the control
saline group, total TH-positive neuronal number was still 2.5 fold higher than in the PQWater group (PO.OOl) and 1.5 fold higher than the PQ-WS-placebo group (P<0.001).
Interestingly, the counts also revealed a higher number of TH-immunopositive neurons in
the PQ-Placebo group in comparison to the PQ-Water group (PO.OOl), although this
difference was not as clear in the microscopic images (Figure 3.2C). It should be noted,
that the placebo solution contained PTS, a derivatised form of vitamin E, which could be
responsible for the observed neuroprotection.
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Figure 3.2 Immunohistochemical evaluation of midbrain damage. Rats were
sacrificed, following the completion of experiment #1; brains were fixed, paraffin
embedded and processed for immunohistochemistry. Images were captured using a Carl
Zeiss Axiovert 200M microscope. Representative photomicrographs of midbrain sections
showing TH-immunopositive neurons from saline injected rats (A), PQ injected water fed
rats (B), PQ injected placebo fed rats (C) and PQ injected WS-C0Q10 fed rats (D).
Magnification: 10X. Insets (a' to d') show the density of TH-immunopositive neurons
and fibres in the respective groups. Magnification: 20X. The number of THimmunopositive neurons was counted manually (E). Data is shown as mean ± SEM.
Statistically significant differences are indicated as: , between saline injected group and
PQ injected water fed group, P< 0.001; m, between PQ injected water fed group and
both PQ injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.001;111114
between PQ injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.001,
n = 3.
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3.1.2 Biochemical Analysis
The pro-oxidant effects of PQ such as oxidative damage to lipids and other
cellular macromolecules, have been studied in a number of experimental systems and
tissues other than the brain (Di Monte et al. 1986, Tamarit et al. 1998, Cheng et al.
1999). It has been proposed that oxidative stress may initiate PQ-induced apoptotic cell
death in cultures of cerebellar granule cells (Gonzalez-Polo et al. 2004) and may underlie
tissue damage when PQ is directly infused into the SN of rats (Mollace et al. 2003). In
vitro studies in our lab also indicated a number of biochemical changes induced by PQ
treatment including oxidative stress, activation of caspases and loss of mitochondrial
membrane potential (McCarthy et al. 2004).
The most common tests used to analyse the damage caused by ROS include
measuring the levels of oxidatively modified proteins, DNA and lipids. Also, the levels of
antioxidants such as reduced form of glutathione are indicators of oxidative stress levels.

3.1.2.1 Evaluation of Levels Oxidative Stress Markers
3.1.2.1.1 Assessment of Reduced Glutathione after PQ Administration
In order to assess PQ-induced oxidative damage in different regions of the brain,
and to assess if WS-CoQio could this prevent this damage, I measured GSH content
(Figure 3.3) in the midbrain of the rats following the three injection regime. These rats
received 10 mg/kg of PQ once a week for three weeks. GSH is an abundant anti-oxidant,
found in many tissues and is known to protect cells against oxidative damage (Dringen
and Hirrlinger 2003). Depletion in GSH levels have been observed in the MPTP model of
PD (Liang et al. 2007).
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In my study, animals from experiment #2 were sacrificed, brain tissues were
harvested and then dissected as well as homogenised and the DTNB assay was performed
as described in Materials and Methods. I compared the levels of GSH in the brains of PQinjected groups (Placebo-fed and WS-CoQio fed groups) to the saline injected groups
(Placebo-fed and WS-CoQio- fed groups).
Results of GSH content analysis was expressed as percent control; the placebosaline group was considered the control group. In the midbrain, the GSH content in the
PQ-Placebo group (8.11 ± 0.7) was reduced by half as compared with the saline placebo
(16.34 ± 5.7) and saline WS-CoQio (13.19 ± 1.8) groups (PO.OOl), consistent with it
being utilized to combat the effects of PQ in the midbrain (Figure 3.3B). However, the
GSH level was maintained at nearly control level in the PQ-WS-CoQio group (11.05 ±
1.1) compared with both PQ injected groups, ,P<0.001).
A similar outcome was seen in the striatum (Figure 3.3A), where GSH levels in
the PQ-Placebo (6.9 ± 0.69) group was reduced to half compared to the saline WS-CoQio
(11.39 ± 1.86) group and saline placebo (15.46 ± 1.21) group. Furthermore, WS-CoQio
offered protection against PQ-induced loss in GSH levels (10.66 ± 2.54). These results
suggest that the anti-oxidant content of WS-CoQio formulation offset PQ effects, sparing
the GSH system. Two way ANOVA revealed a statistical significance in the GSH levels
(comparing saline vs. PQ-injected groups, as well as placebo and WS-CoQio groups, p<0.
05).
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Figure 3.3 Levels of reduced GSH in the striatum and midbrain. Following the
completion of experiment #2 rats were sacrificed and midbrain tissue was homogenized
and assayed for GSH in the striatum (A) and midbrain (B). Data (mean ± SEM) was
normalized to that of saline injected placebo fed group, which was taken as 100%. A)
Statistically significant differences are indicated as:
between saline injected placebo
###
fed group and PQ injected placebo fed group, P< 0.001; , between PQ injected placebo
fed group and saline injected WS-CoQio fed group, P< 0.001; HHH between PQ injected
placebo fed group and PQ injected WS-CoQio fed group, P< 0.001, (n = 3).
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3.1.2.1.2. Assessment of Levels of Lipid Peroxidation. Another marker of
oxidative stress is lipid peroxidation. Recent studies report a higher malondialdehyde
(MDA) level (Schmuck et al. 2002) and increased lipid peroxidation in the substantia
nigra region of PD brains (McCormack et al. 2006). I measured the content of MDA, the
product of lipid peroxidation, to assess the degree of PQ-induced lipid damage in the
midbrain (Figure 3.4). There was particularly evident damage in PQ-Placebo (139.34 ±
20.34) group as indicated by a significantly increased MDA level in comparison to
groups injected with PQ and protected with WS-CoQio (P<0.05). Again, the MDA levels
in PQ-WS-CoQio (93.90 ± 13.19) was nearly the same as the saline placebo (100 ± 0) and
saline WS-CoQio (73.70 ± 23.4) groups and were significantly lower than in PQ-Placebo
group (P<0.05). Thus, these results indicated that PQ injections lead to increased lipid
peroxidation, which was mitigated by WS-CoQio.
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Figure 3.4 Levels of lipid peroxidation in the midbrain. Following experiment 2, rats
were sacrificed; midbrain tissue was homogenized and assayed for MDA levels. Data
(Mean ± SEM) was normalized to that of saline injected placebo fed group, which was
taken as 100 %. Statistically significant differences are indicated as: , between saline
injected placebo fed group and PQ injected placebo fed group, P< 0.05; * between PQ
injected placebo fed group and saline injected WS-CoQio fed group;
between PQ
injected placebo fed group and PQ injected WS-CoQio fed group, P< 0.05 (n = 2).
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3.1.2.2. Assessment of ATP Levels in the Striatum and Midbrain
3.1.2.2.1 Evaluating the Levels of Mitochondrial ATP Levels after PQ
Administration
Studies have shown that toxins such as MPTP once accumulated in neurons, may
cause damage by impairing mitochondrial function. As a consequence, cellular energy
supplies in the form of ATP would be rapidly consumed, leaving cells unable to perform
functions critical for their survival (Scotcher et ah 1990). Cell death after exposure to
MPTP and MPP+ has been linked to ATP depletion in studies using hepatocytes and PC
12 cells as in vitro model systems (Di Monte et ah 1986, Denton and Howard 1987,
Singh et ah 1988). It has been shown that PQ causes mitochondrial dysfunction by
inhibiting the electron transport chain, resulting in increased ROS production (DinisOliveira et ah 2006). In vitro studies in our lab indicated that PQ treatment caused
depletion in ATP levels. To analyse if PQ could induce ATP depletion and accordingly,
whether WS-CoQio could prevent ATP depletion, a luciferin-luciferase assay was
performed using the midbrain and striatum to measure mitochondrial ATP production.
The results were expressed as percent control where the placebo saline group was used as
the control group.
As shown in figure 3.5, I observed that both PQ-injected groups significantly
decreased their ATP levels compared to that maintained by the control saline-placebo
group in both the midbrain and striatum. In the midbrain (Figure 3.5A), the PQ-CoQio
rats showed far less of a decline than the PQ-Placebo rats (67% vs. 52%), which missed
significance (p=0.086). Unexpectedly, the saline-CoQio group slightly (78%) but
significantly had reduced ATP levels.
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Similar results were observed in the striatum region (Figure 3.5B), where the PQPlacebo rats showed about 30% decline in the ATP levels as compared to the salineplacebo and the PQ-WS-C0Q10 animals. The ATP levels in the PQ-WS-C0Q10 group
were near control (saline-placebo group). Therefore, our results indicate that WS-C0Q10
moderated mitochondrial dysfunction caused by PQ.
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Figure 3.5 Levels of mitochondrial ATP in the midbrain(A) and the striatum(B).
Following experiment 2, animals were sacrificed and fresh midbrain and striatum
homogenates were obtained. Mitochondrial fractions were separated and then subjected
to a luciferin-luciferase assay to detect mitochondrial ATP levels. In both regions, the
results were normalised to saline-placebo group (control group). * reveals statistical
significance, p<0.05, (n=3).
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3.1.2.2.2. Measurement of Total Cellular ATP Contents After PQ Exposure
In the previous experiment, only the mitochondrial ATP was measured. However,
these results do not reflect total ATP levels. I performed a luciferin-luciferase assay on
the midbrain extracts to establish a steady-state content of ATP in the PQ-injected rats
(Figure 3.6). The data revealed a nearly 50% drop in the ATP level in PQ-Water when
compared to the saline injected group (41.4% of control, PO.OOl). The ATP levels in the
PQ-injected animals were also lower than the saline group. The ATP levels were
significantly higher, especially in the PQ-WS-CoQio group than in unprotected PQinjected group compared to the PQ-Water group (jP<0.05).
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Figure 3.6 Levels of total cellular ATP in the midbrain. Following experiment 1, rats
were sacrificed; midbrain tissue was homogenized and assayed for net ATP content using
the luciferin-luciferase assay as described in Materials and Methods. Data (mean ± SEM)
was expressed as percent of control, where Saline-Water group was used as the control
group. Statistically significant differences are shown as: ***. between saline injected and
PQ injected water fed group, P< 0.001; between PQ injected water fed group and PQ
injected placebo fed group, P< 0.05; H, between PQ injected water fed group and PQ
injected WS-CoQio fed group, P< 0.05 (n = 2).
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3.1.3 Behavioural Assessments
To determine the effects of PQ on Long Evans hooded rats and the potential
neuroprotective effects of WS-CoQio, biochemical, histochemical as well as behavioural
parameters were examined. Specific behavioural changes are attributed to PD, and
analysis of these changes is fundamental when using an animal model of PD. For this
purpose, the rats were subjected to a series of rotorod tests over the course of the three
injection regime (experiment 2) to measure spontaneous changes in their balancing
behaviour. These neuroprotective effects were accompanied by maintenance or even
improved balance on the rotorod (Figure 3.7A). In fact, animals of the PQ injected WSC0Q10 group behaved the same on the rotorod tests as animals in both saline injected
groups.

3.1.3.1. Proportion of Time Spent in Walking Backwards
Changes in the amount of time that rats in each group spent walking backward
over the three test sessions (pre-injection, mid-injection, post-injection) are shown in
figure 3.7A. Although all groups spent a greater proportion of their time walking forward,
they spent 30% to 40% of their time walking backwards on their first (pre-injection) test.
Rats in the PQ-Placebo group were the only ones that steadily reduced the amount of time
spent spontaneously walking backward. In fact, during the post-injection test they almost
exclusively maintained a forward walking gait. The three-way ANOVA on the
transformed data uncovered a significant injection type among all three factors, p=0.015.
One-way within-subjects ANOVAs for each group revealed that only rats in the PQ-
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placebo group significantly reduced their proportion of walking backwards, /?<0.01.
There were no statistically significant effects for any changes in the other three groups.

3.1.3.2. Vertical and Horizontal Nose Positions
Separate analyses of rats' vertical and horizontal nose positions while on the
rotorod did not uncover any significant changes reflecting the experimental treatments
(i.e., PQ vs. saline injections or placebo vs. C0Q10 supplementation). As shown in figure
3.7B, rats tended to walk forward with their noses slightly below the top of the rotorod
(below the horizontal line at 210 pixels) and extended well away from it (177 pixels from
the left vertical line). When rats did walk backwards, they also tended to extend their
noses slightly below the top of and away from the rotorod.
In summary, I found clear evidence of a motor balance dysfunction in rats that
had suffered PQ-induced neuronal loss in the SNc (PQ-Placebo group). These rats
drastically reduced their tendency to spontaneously turn around and walk backwards
during and following their series of injections. On the other hand, PQ-injected rats whose
SNc area was protected by WS-CoQio (PQ-CoQio group) retained their pre-injection
levels of the backward gait on the final post-injection. Thus this group did not differ
statistically from either of the saline-injected groups.
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Figure 3.7 Behavioural assessments. Rats were trained on the rotorod and behavioural
testing was carried out. (A) Rats were placed on a moving rotorod and the time spent
walking backwards on the rotorod was monitored. Measurements were made before (preinjection), during (mid-injection) and after (post-injections) the PQ-injections. The data
points represent the mean proportion of time spent walking backwards during each
testing session (n=6). (B) Representative image of the tracking format used for
determining forward/backward walking posture as well as the location of nose on the
rotorod. The horizontal line is positioned at the top of the rotorod and the two vertical
lines determine the forward and backward walking positions. Any nose locations between
the left and right vertical lines were not counted.
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Thus treating animals with three injections of 10 mg/kg PQ not only induced
neuronal loss in the SNc but also caused behavioural deficits and increased oxidative
stress levels and decreased ATP levels in the midbrain and striatum. Interestingly, prefeeding with WS-C0Q10 substantially prevented loss of DA neurons, decreased oxidative
stress and maintained and ATP levels near control. Moreover, behavioural deficits were
also significantly reduced by WS-C0Q10 pre-feeding.

3.2 Specificity of Paraquat Neurotoxicity and Evaluation of Neuroprotection by WSC0Q10 at Higher Doses of Paraquat
This study was designed to evaluate:
1. If higher doses of PQ could lead to a greater loss of DA neurons.
2. Specificity of PQ-induced neuronal cell death
3. Effects of prophylactic and therapeutic use of WS-CoQio (pre- and post- injection
feeding) on neuroprotection
4. Effects of age on PQ-induced toxicity

I wanted to evaluate the effects of higher doses of PQ and examine if a higher
dose would cause increased death of DA neurons. While trying to improve the existing
model, I came across the advantages of using multiple insults to cause death of DA
neurons, in the literature. Reportedly, eight injections of 10 mg/kg PQ alone or 10 mg/kg
PQ in combination with another fungicide, maneb (30 mg/kg) were used to induce death
of DA neurons (Thiruchelvam et al. 2000a, Thiruchelvam et al. 2000b, Cicchetti et al.
2005, Saint-Pierre et al. 2006). Therefore I began a study involving a combination of 10
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mg/kg PQ and 30 mg/kg maneb injected twice a week for four weeks. This combination
proved to be fatal to a number of rats and was therefore discontinued. I decided use eight
injections of 10 mg/kg PQ alone (twice a week for four weeks) and analyze if more
neuronal damage could occur with this regime than with only three injections. However,
this regime also proved to be fatal Long Evans hooded rats.
Since the eight injection PQ regime was highly toxic to the rats, I decided to use
five injections of 10 mg/kg PQ, and evaluate if this regime could increase the loss of DA
neurons compared to three injections. The five injection PQ regime did not cause any
fatalities. Therefore preliminary studies were carried out to evaluate the nigral loss and
biochemical parameters.

3.2.1

Evaluating the Effects of the Five Injections of PQ and the Efficacy of
WS-CoQio as a Prophylactic and Therapeutic Agent on Nigral Cells

Our studies with three injections of PQ clearly revealed the neuroprotective effect of
WS-CoQio as a prophylactic agent. However, the ability of this compound as a
therapeutic agent needed to be studied. To study the effects of WS-CoQio as a
prophylactic agent, WS-CoQio feeding was started before the commencement of PQ
injections; to investigate the therapeutic abilities of WS-CoQio, WS-CoQio feeding began
only after the last injection. For comparison, the DA neuronal numbers were counted
using TH-immunostaining.
The number of DA neurons was estimated by counting TH-immunopositive
neurons in the substantia nigra pars compacta. Assessment of midbrain sections showed a
clear decrease in the density of TH-immunopositive neurons in rats injected five times
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with 10 mg/kg PQ. In this preliminary study, I compared the prophylactic effects of WSC0Q10 (pre-fed) to its therapeutic effects (post-fed). As shown in figure 3.8(A-B) rats
belonging to the PQ-Water group were vulnerable to PQ, as it caused about 30%
reduction of TH-positive neurons compared to the saline injected groups. Rats belonging
to the PQ-Placebo pre-fed group showed a decline of about 26%, while rats of the PQCoQio pre-fed group showed only about 14% loss in the number of TH-positive neurons,
compared to the control group. When WS-CoQio is fed after PQ injections, it still offered
neuroprotection against PQ toxicity and prevented further loss of DA neurons (28%
decline in TH-immunopositive cells in PQ-CoQio post-fed rats compared to about 40%
decline in PQ-Placebo post-fed rats) as indicated in figure 3.8A-B.
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Figure 3.8 Evaluation of neuroprotective effects of WS-CoQio as a prophylactic and
therapeutic agent. (A) Pictures of TH-immunostained sections were obtained by using a
Nikon ECLIPSE E800 microscope. Original magnification 10X. (B) TH-positive neurons
were counted manually in the substantia nigra pars compacta of rats treated with five
injections of 10 mg/kg PQ. Data is represented as percentage of control. Mean ±SEM, n =
2.
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3.2.2 Assessment of Oxidative Stress Levels
3.2.2.1 Evaluating Levels of Reduced Glutathione after PQ Treatment
As mentioned earlier, GSH is a very important anti-oxidant in the brain. In this
study, the GSH content was measured from the midbrain. The results were
normalised to the Saline-Water (control) group. The effects of prophylactic versus
therapeutic applications of WS-C0Q10 on levels of GSH after PQ treatment were
analysed. There was a loss of about 40% in GSH content in the PQ-Water group as
compared to the Saline-Water (control) group (Figure 3.9). Although the PQ-Placebo
pre-fed group showed higher GSH levels than PQ-Water group, the GSH levels were
maintained at a near control level in the PQ-WS-CoQio pre-fed group. Interestingly,
the amount of GSH in the PQ-CoQio post-fed group was maintained at a slightly
higher level as compared to PQ-Water and PQ-Placebo post-fed groups.
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Midbrain

Figure 3.9 Evaluating levels of reduced GSH in the midbrain. After the completion of
the experiment, rats were sacrificed, midbrain tissue was homogenized and assayed for
GSH Data (Mean ± SEM) was normalized to that of Saline-Water group, which was
taken as 100 %. n = 2.
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3.2.2.2 Evaluating the Levels of Lipid Peroxidation in the Midbrain
As mentioned earlier, levels of oxidative stress can be monitored by evaluating
the levels of lipid peroxidation. I measured the content of MDA, the product of lipid
peroxidation, to assess the degree of PQ-induced lipid damage in the midbrain. The
results were normalised to the Saline-Water or the control group. The effects of
prophylactic versus therapeutic applications of WS-C0Q10 on levels of lipid peroxidation
after PQ treatment were analysed. There was an increase of about 34% in lipid
peroxidation levels in the PQ-Water group as compared to the Saline-Water group
(Figure 3.10). Although the PQ-Placebo pre-fed group showed lower lipid peroxidation
levels than PQ-Water group, the lipid peroxidation levels were maintained at a slightly
lower level in the PQ-WS-CoQio pre-fed group. Furthermore, the lipid peroxidation
levels in the PQ-WS-CoQio post-fed group were maintained at a near control level as
compared to PQ-Water and PQ-Placebo post-fed groups. Thus WS-CoQio does offer
protection against PQ-induced oxidative stress.
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Figure 3.10 Evaluating the levels of lipid peroxidation in the midbrain. After the
completion of experiment, rats were sacrificed, midbrain tissue was homogenized and
assayed for lipid peroxidation. Data (Mean ± SEM) was normalized to that of SalineWater group, which was taken as 100 %. n = 2.
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3.2.3 Analyzing the Levels of Total ATP in the Midbrain
The net cellular ATP content, however, reflects a balance between energy production
and consumption, in which an increase would be expected under oxidative stress
conditions since ROS detoxifying enzymes are energy dependent. I performed a luciferinluciferase assay on the midbrain extracts to establish a steady-state content of ATP in the
PQ-injected rats (Figure 3.11). The results were normalised to the saline-water or the
control group. The effects of prophylactic versus therapeutic applications of WS-C0Q10
on levels of total ATP after PQ treatment were analysed. The data revealed a 44% loss in
the ATP levels in PQ-Water group when compared to the Saline-Water group. The ATP
levels in the all the PQ-injected rats were also lower than the Saline-Water (control)
group. Although the PQ-Placebo pre-fed group showed higher ATP levels than PQ-Water
group, the ATP levels were maintained even higher in the PQ-WS-CoQio pre-fed group.
Interestingly, the amount of ATP in the PQ-CoQio post fed was maintained at a slightly
higher level as compared to PQ-Water and PQ-Placebo post-fed groups.
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Figure 3.11 Evaluating the levels of total ATP in the midbrain. After the completion
of experiment, rats were sacrificed, midbrain tissue was homogenized and assayed for
ATP levels using luciferin-luciferase method. Data (Mean ± SEM) was normalized to that
of Saline-Water group, which was taken as 100 %. n = 2.
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3.2.4 Evaluating the Effect of PQ on Protein Expression. Western blot analysis
was performed on the midbrain homogenates to evaluate PQ induced response on the
level of proteins such as tyrosine hydroxylase, parkin, a-synuclein and GFAP. As
mentioned earlier, TH is a marker for DA neurons. Preliminary results indicate a decrease
in the levels of TH in all the rats subjected to PQ treatment as compared to their saline
injected counterparts, correlating to the loss of DA neurons, a-synuclein expression is
increased in midbrains of rats challenged by PQ (Bove et al. 2005). Up regulation of this
protein has been observed in MPTP-treated squirrel monkeys (McCormack et al. 2008).
Our preliminary results indicate no change in the expression levels of a-synuclein post
PQ injections. Parkin may be critical for protecting DA neurons from toxic insults by
targeting misfolded or oxidatively damaged proteins for proteasomal degradation (Perez
et al. 2005). When I examined parkin levels, they remained unchanged between saline
and PQ-injected rats (Figure 3.12). These are preliminary results and no conclusions can
be drawn from this data.
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Figure 3.12 Evaluating the levels of protein expression. Western blots of TH, parkin,
a-synuclein and GFAP proteins in the midbrain of rats treated with 10 mg/kg PQ once a
week for five weeks. Midbrain homogenates were subjected to western blot analysis for
analyzing the expression levels of different proteins. Ponceau S staining was performed
to confirm equal loading in all wells.
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3.2.5 PQ-induced Selective Damage of DA Neurons in the SNc
3.2.5.1 Selectivity of PQ-induced Neuronal Loss
Results have indicated a loss in DA neurons after PQ injections. The selectivity
of PQ toxicity was further evaluated by immunohistochemical examination of neurons in
the hippocampus region, cortex and the cerebellum. I stained the sections (coronal
sections across the substantia nigra region) with anti-NeuN, as well as hematoxylin and
eosin (H&E).
H&E staining has been widely used to label viable and damaged cells in the brain
(Schmued et al. 1997). Hematoxylin stains nuclei blue and eosin stains cytoplasm pink.
NeuN is a neuronal-specific protein (Mullen et al. 1992) that is frequently used as a
specific marker for viable and intact neurons (Mullen et al. 1992, Xu et al. 2002, Hassen
et al. 2004). Immunohistochemistry of NeuN shows that this protein is visible both in
nuclei and in portions of the cytoplasm of neurons, such as the cell body, axons and
dendrite processes (Mullen et al. 1992).
Neurons in the hippocampus are vulnerable to a variety of toxins
(Stoltenburgdidinger 1994, McCormack et al. 2002) and therefore were identified as a
cell population that could be a potential, albeit non-intended target of PQ toxicity. NeuN
staining of the hippocampus region in the saline and PQ-injected rats did not reveal any
significant decrease in the numbers of neurons as shown in figure 3.13A. A similar result
was observed for NeuN staining of the cortex (Figure 3.13B). However, a decrease in the
number of NeuN positive cells was observed in the midbrain region of rats treated with
PQ. Moreover, H& E staining of saline and PQ treated rats did not reveal any damage to
cells in the hippocampus region and cerebellum. The gross morphology of the midbrain

also did not seem to be affected by PQ treatment (Figure 3.13D). These studies were
performed by a neurologist (Dr. T.S. Sridhar) who interpreted the results (in a blind
study). These results need to be quantified and also confirmed.
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Figure 3.13 Effects of PQ on neuronal cells in different areas of the brain. Coronal
brain sections were immuno-stained for NeuN as well as stained with Hemtoxylin and
Eosin (H&E). Pictures were obtained using a Leica DM IRB microscope. NeuN immunostaining in hippocampus region (A), the cortex (B) and the midbrain region (C). H&E
staining of the hippocampus, midbrain and cerebellum (D). Pictures were taken at 40 X
magnification.
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3.2.5.2 PQ Treatment does not Cause any Damage to Peripheral Tissue
Most of the rats treated with PQ gained weight progressively, albeit a little slower
as compared to their saline counterparts especially during the weeks of injections. No
significant weight loss was observed between the saline and PQ-treated rats (Figure
3.14). More importantly, there were no fatalities after five PQ injections.
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Figure 3.14 Weights of rats for the five injection PQ regime. Weights were recorded
for each animal every week. An average weight of the four animals in a cage is shown
here (n=4).
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Since the herbicide was injected intraperitoneally, a general pathological analysis
of the liver, kidneys and lungs was carried out. The liver and kidneys are responsible for
elimination of toxins from the body. H&E stained sections of these tissues were evaluated
by a pathologist (Dr. Jyothi S. Prabhu) in a blind study, without the knowledge of
treatment groups. Results revealed that there was no damage to the liver or kidneys
(Figure 3.15). Acute PQ exposure has been shown to cause severe damage to the lungs
(Dinis-Oliveira et al. 2006). The analysis of the lung tissue revealed that there was blood
present in the tissue making it difficult to draw any conclusions. The arrows indicate the
presence of blood cells.
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Figure 3.15 Analysis of peripheral organs after PQ exposure. The lungs, liver and
kidneys were fixed and 8 p. sections were obtained from different parts of the organs and
stained with H&E. The pictures of the lungs and liver were taken at 40X magnification
while the pictures of the kidney were taken at 63X magnification.
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3.2.6 PQ Induces Astroglia Response in the Midbrain
Several studies have documented that glial activation and neuroinflammatory
processes play an important role in the pathogenesis of PD (Hirsch et al. et al. 2005,
Wersinger and Sidhu 2006, Rogers 2008). Glial fibrillary acidic protein (GFAP), which is
abundantly expressed by astrocytes in the central nervous system (CNS), is widely used
as a marker of astrocytic activation (Eng et al. 2000). It has shown in mice that PQ
exposure does lead to inflammation (McCormack et al. 2002). To evaluate the effects of
PQ on inflammation in Long Evans Hooded rats, I immunostained midbrain sections for
GFAP. In order to do so, rats were injected with 10 mg/kg PQ (once a week for five
weeks), sacrificed and perfused. The brains were fixed in 10% buffered formaldehyde,
sectioned and stained with anti-GFAP antibody as in Materials and Methods. The
staining revealed increased astrocyte expression of GFAP in all PQ-injected groups
(Figure 3.16B-D) when compared to the saline-injected rats (Figure 3.16A).The strongest
GFAP response, however, was seen in the brains of the rats that drank the WS-CoQio
supplemented water. Under a higher magnification, the astrocyte processes appeared to
be thicker and fibrous (hypertrophic), typical of reactive astrocytes, which were rarely
seen in the saline-injected rats receiving regular drinking water (Figure 3.16 b' c' d' as
compared to a'). The quantitative cell counts confirmed the increased presence of reactive
astrocytes in the PQ-injected groups, but especially in the WS-CoQio groups (Figure
3.16E). The number of counted astrocytes in the WS-CoQio groups was nearly double
that in the saline group and even the PQ-Placebo fed and PQ-WS-CoQio fed groups. The
astrocytic presence in the later two groups was also significantly higher than in the
control group (Saline-Water). Thus, the neuroprotective effects of WS-CoQio were
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clearly associated with the significantly induced astroglia response (PQ-WS-CoQio fed
group vs. saline injected group, PO.OOl; PQ-WS-CoQio fed group vs. PQ-Placebo fed
group, PO.OOl).
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Figure 3.16 Midbrain astroglia responses. Brains from rats were fixed, paraffin
embedded and processed for immimohistochemistry. Representative photomicrographs of
midbrain sections showing GFAP-immunopositive astrocytes from saline-injected group
(A), Saline-injected Water-fed group (B), PQ-injected Water-fed group (C) PQ-injected
Placebo-fed group and (D) PQ-injected WS-CoQio-fed group. Magnification: 20X. Insets
(a' to d') show a single cell at higher magnification from the respective groups. (E) The
number of astrocytes with increased GFAP expression was scored; at least 300-500 cells
were counted at 40X magnification in 2 separate experiments. The number of astrocytes
in control (Saline-Water group) was taken as 100% and the treated groups were expressed
as percentage of control. Statistically significant differences are indicated as:
between
saline-injected group and PQ-injected Water-fed group, P< 0.001; ###, between PQ
injected Water-fed group and both PQ-injected Placebo-fed group and PQ injected WSCoQio fed group, P< 0.001;HHH, between PQ-injected Placebo-fed group and PQ-injected
WS-CoQio-fed group, P< 0.001, (n=2).
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Furthermore, I observed astrocyte activation in the brain upon PQ treatment,
especially in the hippocampus region. Preliminary results revealed that increased
numbers of activated astrocytes were seen in the PQ-injected rats as compared to the
saline-injected rats (Figure 3.17A). Interestingly, I observed that the orientation of
astrocytes found above the hippocampus was unique in both the saline and PQ injected
rats and there was more activation of these cells after PQ treatment (Figure 3.17B).
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Figure 3.17 Astroglia responses in other brain areas. Brains from rats were fixed,
paraffin embedded and processed for immunohistochemistry as described in the Materials
and Methods. Representative immunofluorescence images of GFAP-immunoreactive
astrocytes from hippocampus region (A), and above the hippocampus region (B) of rats at
40X magnification on a Leica DM IRB microscope. (n=l)
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3.2.6.1 Evaluating the Levels of Different Chemokines and Cytokines after
PQ Administration
Cytokines and chemokines are extracellular signaling molecules that mediate
communication between cells. They are released from cells and play pivotal roles in
many biological processes such as cellular growth, differentiation, migration, gene
expression, immunity and inflammation (Borish and Steinke 2003). I observed activation
of astroglia in the midbrain and hippocampus after PQ exposure. Since the main
communication signals used by microglia are cytokines and chemokines (Rock and
Peterson 2006) I then measured the levels of various cytokines, using a cytokine array kit.
This assay allowed us to determine the levels of multiple cytokines in a single experiment
and to understand if the cytokines being over expressed are neuroprotective, or if they
mediate neurotoxicity. Results showed that after injections with PQ, the CNTF,
Fractalkine or CX3CL1, sICAM or CD54, LEX, L-Selectin or CD62L / LECAM-1 and
Thymus cytokine or CXCL-7 are over expressed. In the PQ-CoQio group, there was over
expression of the cytokine L-Selectin or CD62L / LECAM-1 indicated by the red circle
(Figure 3.18). Our results are preliminary and need to be confirmed by further
experiments.
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Figure 3.18 Evaluating the levels of cytokines/chemokines. The midbrain homogenates
from saline and PQ- injected rats were subjected to a cytokine array. The results show the
expression profiles of different cytokines/chemokines.
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3.2.7 Effects of Age on PQ-Induced Toxicity
3.2.7.1 Effect of PQ on Nigral Cells
Microscopic assessment of midbrain sections stained with an antibody against
TH showed a clear decrease in the density of TH-positive neurons after the last of the five
10 mg/kg PQ injections. The number of DA neurons was estimated by counting THimmunopositive cells in the SNc manually. In this preliminary study, I compared the
effects of PQ on old rats. The data were normalised to the Saline-Water group which was
considered the control group. As shown in figure 3.19(A-B), rats belonging to the PQWater group were vulnerable to PQ which caused about 50% reduction of TH-positive
neurons when compared to the saline injected counterparts. Rats belonging to the PQPlacebo showed a decline of about 35%, while those belonging to the PQ-CoQio group
showed only about a 26% loss in the number of TH-positive neurons when compared to
control.
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Figure 3.19 Effects of PQ on nigral cells in old rats. (A) Pictures of TH-immunostained sections from old rats using the Leica DM IRB microscope. Original
magnification 10X. (B) TH-positive neurons were counted manually in the SNc of rats
treated with five injections of 10 mg/kg PQ. The data (Mean ±SEM) were normalised to
the Saline-Water group which was considered as the control group (n=l).
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3.2.7.2 Biochemical Analysis
3.2.7.2.1 Analysis of GSH Levels
In this study, GSH content was measured from the midbrain. The effect of PQ on
levels of GSH in old and young rats was analysed. In the young rats, a loss of about 40%
in GSH content in the PQ-Water group as compared to the Saline-Water (control) group
was observed (Figure 3.20). In the PQ-CoQio group, higher levels of GSH were observed.
However, in the case of the old rats, the saline-injected rat had a lower level of GSH as
compared to the young counterparts. There was a loss of about 60% GSH content in the
PQ-Water group when compared to the saline-water rat.
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Figure 3.20 Evaluating GSH levels in old and young rats. Rats were sacrificed and
midbrain homogenates were subjected to GSH assay. Data (mean ±SEM) is represented
as percentage of control, n =2.
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3.3 Evaluation of the Probable Mechanism of C0Q10 Neuroprotection
A portion of this study to evaluate the mechanism of neuroprotection by WSCoQlO was done with Dr. Jafar Naderi.
Studies in our lab have shown that WS-C0Q10 can prevent HEK 293 cells
from undergoing apoptosis when exposed to hydrogen peroxide-induced oxidative stress
(Naderi et al. 2006). H^C^-induced mitochondrial membrane collapse and increased ROS
generation is involved in apoptosis (Naderi et al. 2006). Studies in our lab have shown
that oxidative stress induced by either H2O2 or paraquat (PQ) leads to mitochondrial
dysfunction and loss of mitochondrial membrane potential (Somayajulu et al. 2005,
McCarthy et al. 2004). Our studies have also indicated that pre-treatment with WS-C0Q10
prevents the loss of mitochondrial membrane potential (Somayajulu et al. 2005,
McCarthy et al. 2004).
C0Q10 (ubiquinone) is found in inner mitochondrial membrane where it shuttles

electrons from complex-I and I to complex-Ill. I wanted to investigate if protection by
WS-C0Q10 is based on its ability to act as an anti-oxidant, or if this compound is capable
of stabilizing mitochondria under oxidative stress.
In order to examine the role of WS-C0Q10 as an anti-oxidant as well as a stabilizer
of the mitochondria, I used compounds such as complex-I blockers and Bax protein,
which are known to cause damage to mitochondria and then observe the effects of this
formulation.
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3.3.1 WS-CoQio Prevents Mitochondrial ROS Production Induced by Complex-I
Blockers Such as Rotenone and Paraquat
Mitochondrial dysfunction has been associated with increased production of
reactive oxygen species (ROS) (Li et al. 2003). Several studies have shown that
complex-I inhibitors such as rotenone can induce mitochondrial ROS production (Sousa
et al. 2003). I was interested in studying the protective effects of WS-CoQio against
oxidative stress induced mitochondrial damage. In order to study the effects of WSCoQio, isolated mitochondria were pre-treated with WS-CoQio for 20 min and then
treated with 10 fiM rotenone. ROS production was measured using a horseradish
peroxidase-based PHPA oxidation method. This method is used to detect H2O2 that is
produced from intact mitochondria when they are incubated with different mitochondrial
chain substrates and inhibitors.
Results from this study indicate that rotenone-treated mitochondria isolated from
SH-SY5Y cells show a significant increase in the production (p<0.05) of ROS as
compared to control (Figure 3.21A). The mitochondria pre-treated with WS-C0Q10 and
exposed to rotenone showed a significantly lower ROS production compared to those
treated with rotenone alone (p<0.05). Therefore WS-C0Q10 functions at the mitochondrial
level and inhibits mitochondrial ROS production induced by rotenone.
A similar study using PQ was also performed. Our results clearly indicated there
was an increase in mitochondrial ROS production upon PQ treatment. A significant
reduction (p<0.05) in ROS production was observed in mitochondria pre-treated with
WS-C0Q10 and exposed to rotenone (Figure 3.21B). In conclusion, WS-C0Q10 reduces
mitochondrial ROS production induced by complex I inhibitors.
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Figure 3.21 Evaluating ROS production in isolated mitochondria. SH-SY5Y cells
were grown, lysed,mitochondria was isolated and treated with either 10 ^M Rotenone
(A) and 200 |liM PQ (B) in the presence and absence of WS-CoQio- ROS production was
measured using PHPA as described in the Materials and Methods. Statistical significance
is denoted by *, p<0.05.
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3.3.2 WS-CoQio Inhibits ROS Generation Induced by Bax in Isolated Mitochondria
Bax is a pro-apoptotic protein of the Bcl-2 family of proteins that translocates to
the mitochondria during apoptosis, inducing release of mitochondrial components such as
cytochrome c and apoptosis inducing factor (AIF), which activate downstream events that
culminate as apoptosis. Previous studies in our lab have shown that incubating Bax with
isolated mitochondria leads to the production of reactive oxygen species (ROS) and
release of cytochrome c (Gueorguieva et al. 2006). In this study I evaluated the
neuroprotective effects of WS-CoQio on Bax-induced mitochondrial damage. Isolated
mitochondria from normal HEK293 cells were treated with purified Bax protein to
compare the protection offered by WS-CoQio. Our results indicate that ROS production
from isolated mitochondria was increased in the presence of Bax, implying that indeed
Bax causes mitochondrial dysfunction; however, mitochondria pre-treated with WSC0Q10 had significantly inhibited ROS production (Figure 3.22). These results clearly
indicate that WS-CoQio is capable of directly inhibiting Bax-induced mitochondrial
dysfunction in isolated mitochondria.
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Figure 3.22 Evaluating ROS generation in mitochondria isolated from HEK 293
cells treated with Bax in the presence or absence of WS-CoQio. Isolated mitochondria
from 293 cells were incubated with Bax in the presence and absence of WS-CoQio and
ROS production was measured using PHPA as described in the Materials and Methods.
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Chapter 4
Discussion
In this study, I have successfully induced DA neuronal loss specific to the SNc in
Long Evan's hooded rats by administering PQ. Studies have revealed that PQ induces
oxidative stress, mitochondrial dysfunction as well as astrocyte activation. More
importantly, I observed neuroprotection by WS-C0Q10 against PQ-mediated toxicity. This
formulation not only prevented neuronal loss but also offered protection against oxidative
stress and mitochondrial dysfunction both as a prophylactic and therapeutic agent.
Interestingly,

I

also observed protection against mitochondrial damage induced by

rotenone, PQ and Bax in in vitro studies.

4.1 Animal Models used for Studying PD
In order to better understand the pathogenesis, and develop neuroprotective
strategies, a good and reliable model of PD is pivotal. Until recently, very little was
known about how and why neurodegeneration ensues and progresses in PD. Much of
information regarding the etiology and pathogenesis of PD is obtained from clinical
studies, post-mortem studies, and epidemiological studies. Accessibility to a human brain
is limited because of ethical approval, availability of postmortem brain tissue, and
difficulty in drawing definitive conclusions due to individual variability and differences
in tissue quality (Emborg 2004). The main characteristic of a PD model should be the
loss in DA neurons in the SNc. Although in vitro studies have proved to be a tool in
deciphering many mechanisms, cell culture systems cannot closely replicate the complex
environment in the human brain. Animal models can help to bridge this gap. Compared to
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cell culture studies, animal models can evaluate the degree of impairment in motor
function observed in PD (Emborg 2004). Rodents are a common choice of animals used
to study PD. Rats have been the model choice to study several human diseases. In the
context of neurological sciences, they have proved to be an important tool to study
processes like neural development, diseases, neurodegeneration, addiction and behavior.
There are many advantages of using rats: (1) availability of extensive baseline data for a
meaningful interpretation of experimental data, (2) larger size makes live operations
feasible and (3) certain physiological similarities of rats to humans (Conn 2007).
Recent studies suggest that PD may arise from

a combination of genetic

susceptibility and exposure to environmental toxins (McCormack et al. 2002, Di Monte
2003, Dinis-Oliveira et al. 2006). Indeed, several environmental risk factors such as
metals and herbicides have been linked to the incidence and progression of PD (DinisOliveira et al. 2006). Amongst these factors, the herbicide paraquat (PQ) shows a clear
neurotoxicity in the CNS. PQ was chosen as the toxin to induce Parkinsonism in our
studies because PQ is an environmental toxin and also its chemical structure is similar to
that of MPP+ (Figure 6). Moreover, there is strong evidence of correlation between long
term PQ exposure and increased risk of PD (Uversky 2004). PQ can enter the CNS
through neutral amino acid transporters associated with the blood brain barrier system
(McCormack et al. 2002) and into dopaminergic neurons via DAT (Ossowska et al.
2005a) and damages the SNc neurons in mouse models (McCormack

and Di

Monte2003). It has also been reported that a prolonged exposure to non-pneumotoxic
levels of PQ causes the damage to basal ganglia (Dinis-Oliveira et al. 2006).
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4.2 Challenges Associated in Finding a Neuroprotective Therapy for PD
There is no perfect model of PD to test strategies for neuroprotection, yet the
models in existence do portray the basic characteristics required. Specific requirements
need to be met by an animal model of PD in order to enable the testing of neuroprotective
strategies. These include: (1) induction a replicable nigral lesion; (2) the loss of DA
neurons should occur stably over time without any spontaneous recovery and (3) there
should be a window of opportunity in order to design a neuroprotective strategy. A
successful neuroprotective agent should be able to offer protection from behavioural
impairment, pathological degeneration and neurochemical deficits (Emborg 2004).

4.2.1 Limitations of Current Models used for Neuroprotection
Cell culture systems are very essential tools to screen compounds. Most putative
neuroprotective drugs are tested first on cultured neurons to determine whether they can
protect cells from a variety of toxins. However, cell culture models do not provide insight
into how a drug will behave in a complex organism. In order to evaluate the capacity of a
drug to protect DA neurons from toxic insults, its side effects and treatment-associated
complications, in vivo models are indispensable.

4.2.1.1 Drawbacks of Animal Models used to Study PD
PD a complex disease occurs primarily in the SNc but degenerative changes also
occur in the central and peripheral nervous system (Lang 2004a). Several models
currently in use, exhibit the characteristic features of PD, but none of them closely mimic
the complex features of human PD.
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Rodent models (mice, rats) are advantageous because they are easily accessible ,
their reproduction rates are high and are they are easy to house (only a small living
space, simple feeding and drinking schedules is needed) (Emborg 2004). A varied
susceptibility exists between species as to how they respond to neurotoxins. For example,
mice are more susceptible to MPTP than rats. Besides this, different strains of mice and
some even within a given strain exhibit different sensitivity to MPTP (Sedelis et al.
2003). Furthermore, age, gender and body weight also play an important role in
determining the sensitivity of an animal to neurotoxins (Przedborski and Vila 2001).
Similar observations have been made in terms of rats. For example, Lewis rats require
two fold higher dosing of 6-OHDA than Fischer or Sprague-Dawley rats. Interestingly,
when rotenone is administered in Lewis rats, there is less variability and more
consistency compared to Sprague-Dawley rats (Betarbet et al. 2002). Evidence of
neuroprotection in rodents does not guarantee similar results in non-human primate
models, given the larger volume and complexity of a monkey brain. However, translation
to human subjects may prove to be even more intricate (Emborg 2004). The advantage of
using an animal model is to obtain a phylogenetic perspective about the odds of success
when translating a therapy to humans. In summary, due to the several advantages of
utilizing animal models, they have been developed to test neuroprotective strategies in
neurodegenerative disorders. However, these models are ongoing efforts of improvising
and improving existing techniques to evaluate neuroprotective compounds.
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4.2.1.2 The Precise Causative Factors of PD are Unknown
One of the biggest challenges in developing neuroprotective strategies is that the
exact causative factors of PD remain elusive. While some familial cases of PD are linked
with a particular gene mutation, most cases occur sporadically and are idiopathic. If the
precise mechanisms underlying cell death in PD could be determined, this may allow the
identification of probable targets for the development of putative neuroprotective agents
(Olanow et al. 2008). Current drugs have focused on blocking oxidative stress,
excitotoxicity, mitochondrial dysfunction, and signaling pathways that might be
connected with apoptosis. Nonetheless, it remains vague which, if any, of the proposed
pathogenic mechanisms that have been implicated in PD is primary and initiates the
apoptotic program. It is possible that neuronal cell death in PD occurs as a consequence
of an overlap of multiple pathogenic factors that interact in a complex network,
contributing to neuronal cell death in different individuals. Interestingly, studies have
shown that patients carrying the same gene mutation, and who are family members may
exhibit different clinical symptoms and different pathology (Olanow et al. 2008). This
theory would imply that a combination of various (neuroprotective) agents acting
simultaneously on different mechanisms might be required in order to achieve
neuroprotection.

4.3 PQ-induced Loss of DA Neurons and Dopamine Deficiency in the Striatum
Since the dopaminergic neurons are densely packed in the SNc, loss of these
neurons can be measured by histochemical methods. I have immunostained for TH
because this enzyme is often used as a phenotypical marker to determine neuronal loss.
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The rate of dopaminergic neuronal loss in the SNc may be accelerated by local factors to
which these neurons may be uniquely vulnerable. These factors include free radical
formation, reduced protection from oxidative stress, high levels of DAT, increased iron
concentrations, increased glutamate input and neuromelanin formation (Lang 2004b).
Our data clearly confirmed the toxicity of systemically administered PQ,
especially towards DA neurons of the SNc. Thus, in the first phase of this study, this
herbicide effectively killed approximately 65% DA neurons in adult male Long-Evans
hooded rats and induced PD-like symptoms (Figure 3.2). Similar results have been shown
by (Brooks et al. 1999). They used C57BL/6J strain of mice and used 3 injections of 10
mg/kg paraquat. Their study revealed significant losses of TH positive neurons in the
substantia nigra pars compacta (-61% loss) and their terminals in the striatum (-90%
loss) after treatment with paraquat at the same dosage of the neurotoxin used in our study.
Furthermore, low dose PQ-treated mice (5 mg/kg) showed a 36% loss of dopaminergic
cells (Brooks et al. 1999).
Furthermore, in the second phase of this study, our preliminary results with older
animals showed a loss of about 50% neurons in the substantia nigra pars compacta
(Figure 3.19). This is certainly higher than the 35% loss seen in younger animals (Figure
22). A loss in TH expression levels was clearly observed in all the animals treated with
PQ when compared to saline injected counterparts (Figure 3.12). Older animals, like
humans, develop age-related changes in the nigrostriatal system, which resemble the
early stages of nigrostraital degeneration. The extents of these changes vary from species
to species (Emborg 2004). McCormack et al. showed a loss of about 25% in the
dopaminergic neuronal numbers in C57BL/6 mice which were exposed to 10 mg/kg
paraquat for three weeks (McCormack et al. 2002). Furthermore, their study revealed an
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increased loss of dopaminergic neurons in the SNc of older animals when compared to
their younger counterparts following PQ injections. Eighteen month-old animals exposed
to PQ lost about 35% DA neurons, while five month-old animals showed a loss of about
25% dopaminergic neurons. Similar results have been obtained from paraquat maneb
(PQ/MB) studies in rats (Sprague-Dawleys), where the authors have revealed that older
animals are more susceptible to brain toxicity from PQ/MB exposure (Thiruchelvam et
al. 2003, Saint-Pierre et al. 2006). However, there exists a lot of discrepancy in data
regarding the effects of age on paraquat toxicity. A recent study in mice has shown that
paraquat toxicity is age independent and demonstrated that young animals are as
susceptible as old rats to this particular neurotoxin (Peng et al. 2007). Studies with six to
eight rats (per group) will be needed to establish statistical significance and confirm
preliminary results.
Given the fact that there is variability in the way animals respond to paraquat
treatment, discrepancy in our data is not surprising. There are conflicting reports about
the effects of paraquat following systemic exposure in mice (Bove et al. 2005). Also
there is a strong indication of the variability in the response to toxins within different
species of rats (Emborg 2004). Studies with rotenone have indicated that there is
variability within a batch of animals as to how they respond to rotenone treatment. It has
been reported that while some animals were sensitive to rotenone treatment, others did
not respond to treatment at all (Betarbet et al. 2002).
I noticed that eight injections of 10 mg/kg PQ alone and 10 mg/kg PQ along with
30 mg/kg maneb (Thiruchelvam et al. 2002) proved to be fatal for Long Evans hooded
rats. Animals treated with eight injections of lOmg/kg paraquat alone (twice a week for
four weeks) regime in our lab suffered fatalities before completion of eight injections.
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However, in the first batch, 3 animals (1 from PQ-Water, 1 from Saline-CoQio, 1 from
PQ-Placebo) did not complete the injection regime and died halfway. Therefore I fixed 2
animals from each group in formaldehyde and froze 1 animal from each group to perform
biochemical analysis. In the second batch, 8 animals (4 from PQ-Placebo, 3 PQ-CoQio, 1
from saline- water) did not complete the treatment and died about halfway through the
treatment. I fixed all the animals with 10% buffered formaldehyde and used them for
histochemistry. There were no drastic reductions in weights between the saline and PQ
injected animals (data not shown). Since we did not have statistically sufficient animals,
this study was used for standardising the protocols for immunohistochemistry. However,
this dose seems to be well tolerated by Sprague Dawley rats and C57BL/6 mice
(Thiruchelvam et al. 2000a,b, Cicchetti et al. 2005). This indicates that Long Evan's
hooded rats may be more sensitive to toxins.
Assessment of catecholamine contents in the nigrostriatal system provides a
profile of the production as well as metabolism of dopamine. Previous reports have
indicated that systemic administration of PQ significantly decreased the level of DA and
its metabolites in the striatum. PQ decreased DA level by 20%, DOPAC and HVA
decreased by 35% and 52%, respectively, in mice treated with PQ (Chen et al. 2008). A
loss of about 30% in dopamine levels has been reported in mice after exposure to PQ/MB
(Thiruchelvam et al. 2000a,b). Future experiments will focus on measuring dopamine and
its metabolites.
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4.4 Specificity of PQ-induced Loss of Neurons
Our results have indicated that PQ administration in rats causes the loss of DA
neurons in the SNc. However, immunostaining to count serotonergic and cholinergic
neurons has to performed to ensure specificity of PQ. Studies have shown that PQ enters
DA neurons via DAT present on these neurons (Ossowska et al. 2005b). However,
toxicity to other areas of the brain has not been very well documented. For this reason, I
decided to use a general marker for neurons, namely NeuN, to stain various areas of the
brain during the five injection PQ regime. NeuN is a neuronal-specific protein (Mullen et
al. 1992) that is frequently used as a neuronal marker for viable and intact neurons (Xu et
al. 2002, Hassen et al. 2004). Immunohistochemistry of NeuN shows that the marker is
visible both in nuclei and in portions of the cytoplasm of neurons, such as the cell body,
axons and dendrite processes (Mullen et al. 1992). Data from the second phase of study
clearly revealed that even with a higher dose of PQ, damage was caused specifically to
the DA neurons in the SNc. Results indicated a decrease in NeuN-immunopositive
neurons in the SNc following PQ injections, but no difference in NeuN immunostaining
in other areas of the brain; e.g. hippocampal region and cortex (Figure 3.13 A,B) between
the saline and PQ groups was observed. McCormack et al. (2002) also reported the
specificity of PQ-induced DA loss in mice. Their study revealed that PQ does not target
the hippocampus or the neurons in the substantia nigra pars reticulata (SNr) which are
anatomically adjacent to the SNc where PQ causes damage. Future experiments will
examine the neuronal counts in the ventral tagmental area (VTA) as well as the SNr.
I also stained the brain sections with H&E and pathologists confirmed that no
gross changes in morphology occurred in the brain of rats treated with PQ (Figure
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3.13D). Furthermore, the intraperitoneal treatment did not cause any damage to the liver
or the kidneys (as assessed by pathologists) (Figure 3.15). Damage to lungs due to acute
dosing of PQ has been shown (Dinis-Oliveira et al. 2006). However, due to technical
difficulties, the analysis of the lungs could not be performed.

4.5 The Mechanism of PQ Toxicity
The mechanism of PQ neurotoxicity appears to be mediated by oxidative stress.
Superoxide anion radicals are generated through redox cycling reactions of PQ with
oxygen as well as with NADH-oxidoreductases (Peng et al. 2007) These superoxide
anion radicals can then lead to the formation of ROS (Figures 1.7, 1.8). The damage
inflicted by ROS in tissues can be evaluated by measuring the modifications to
biomolecules such as proteins, DNA and lipids.
Studies have shown that there is a loss in the GSH during oxidative stress. Again,
results revealed a reduced content of GSH in the brains of PQ-treated rats, consistent with
its utilization to combat the effects of PQ (Figures 3.3, 3.9, 3.20). Recent studies have
pointed out that PQ induces alternation of GSH levels in the SNc in mice. Levels of GSH
in the SNc have decreased more for the PQ group (10 mg/kg) than for the control group,
while levels of oxidized glutathione (GSSG) increased in the SNc region (Kang et al.
2009).
Lipid peroxidation is another method to monitor the oxidative damage caused by PQ.
The end products of lipid peroxidation are usually 4-hydroxy nonenal (4-HNE) and
malondialdehyde (MDA). I also attempted to measure the levels of lipid peroxidation by
measuring these end products. Immunostaining procedures for 4-HNE have been
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standardized and will be used to complement the data. I have successfully measured the
levels of MDA using thiobarbituric acid assay. Our results show increased levels of lipid
peroxidation in the SNc in PQ treated animals (Figures 3.5, 3.10). Similar results have
been shown in mice treated with PQ exposure caused an increase in the number of
midbrain cells positive for 4-hydroxy-2-nonenal, a marker of lipid peroxidation
(McCormack et al. 2006). Increased lipid peroxidation in the striatum and midbrain
regions of mice exposed to PQ (Thiruchelvam et al. 2005). Increased lipid peroxidation
could lead to the changes in the membrane properties and affect cellular homeostasis
(Dinis-Oliveira et al. 2006).
Oxidative stress also leads to mitochondrial dysfunction. Production of ROS leads to
increased formation of superoxide anion radical which can then form peroxynitrite by
reacting with nitric oxide. This peroxynitrite can impair the mitochondrial respiratory
chain and lead to decreased ATP synthesis (Ebadi and Sharma 2003). Consistent with
these phenomena, I also found reduced ATP levels in rat brains following PQ exposure
(Figures 3.6, 3.11). Postmortem degradation of ATP is known to occur during tissue
extraction (Delaney and Geiger 1996). Since, the experimental conditions were the same
for all the rats dissected, the postmortem degradation of ATP is relatively the same for all
animals. Moreover, I have measured the relative levels of ATP and compared the results
between different groups. The solution to this issue is using a high-energy focused
microwave irradiation method, which involves rapid inactivation of enzymes and allows
for the measurement of endogenous ATP (Delaney and Geiger 1996). Using in vitro
assays, I have shown that PQ can destabilize the mitochondria from differentiated human
neuroblastoma cells (McCarthy et al. 2004). Therefore, there is strong evidence
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suggesting that dysfunctional mitochondria and oxidative stress are most likely the
significant contributors to the PQ-induced neurotoxicity.
Systemic exposure of rodents to PQ, alone or in combination with the maneb,
mimics the pathological features of PD, such as the intra-neuronal deposition of asynuclein as well the selective degeneration of DA neurons in the SNc (Manning-Bog et
al. 2002, McCormack et al. 2002, Peng et al. 2004). In order to evaluate the levels of asynuclein in the frontal cortex and midbrain, western blot analysis was performed.
However, our results did not show any increase in levels of a-synuclein (Figure 3.12).
Although preliminary, this study needs to be repeated with more animals. Similarly no
increase in the levels of Parkin was observed in our study (Figure 3.12).
I also tried to estimate the levels of iNOS but was not successful. Once activated,
iNOS produces nitric oxide which can react with superoxide anion radical to form
peroxynitrite. One potential target of peroxynitrite is tyrosine hydroxylase (TH).
Inactivation by nitration of TH by peroxynitrite appears to be a key process in the
development of PD in humans (Symeyne and Jackson-Lewis 2005).
Dopamine is also subjected to free radical attack especially by hydroxyl radical
and autooxidation in the extracellular space. Moreover, dopamine can also be nitrated
intracellularly and therefore may cause degeneration of neurons containing this
neurotransmitter (Symeyne and Jackson-Lewis 2005).
Oxidative stress, c-Jun N-terminal kinase activation, and a -synuclein aggregation
are each induced by PQ, but details of the cell death mechanisms involved remain
unclear. Recently, a Bak-dependent cell death mechanism for PQ-induced neurotoxicity
has been reported. PQ-induced biochemical features that were consistent with apoptosis,
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included cytochrome c release, with subsequent caspase-3 and poly (ADP-ribose)
polymerase cleavage (Fei et al. 2008).
In order to make a model of neurodegeneration functionally relevant, a
behavioural component is necessary. Consideration of PQ as a candidate neurotoxicant
requires that systemic delivery not only produces DA neuron loss in the SNc, but also
exhibits the resultant neurobehavioral syndrome reflecting depletion of dopamine
terminals within the striatum. Decreased motor activity has been reported following PQ
exposure in mice (Brooks et al. 1999). Stepping impairments can be assessed using a
rotorod. Stepping impairments are assessed by counting the number of adjusting steps
taken by a rat while moving on a rotating rod. While the animals move on the rotorod,
they are videorecorded from the front,

lateral and posterior views. The recorded

behaviour is then analysed frame by frame (Whishaw et al. 2003). I was interested in
evaluating the translational effects of loss in DA neurons to change in behaviour. In the
first phase of our study, PQ affected rats showed clear signs of deficiency in fine motor
control as indicated by a reduced tendency to turn around and walk backwards on the
rotorod (Figure 3.7). The data for the second phase is currently being analysed.

4.6 Neuroprotective Effects of WS-CoQio
Our results indicate that PQ causes a loss in DA neurons in the SNc, induces
oxidative stress, mitochondrial dysfunction as well as behavioural deficits. Furthermore, I
have established that the brain damage and the performance deficits could be minimized
by giving the animals WS-CoQio, which contained WS-CoQio and derivatised vitamin E
and was provided throughout the duration of the experiment. I eliminated the
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neurotoxicity of PQ by providing the animals with drinking water containing WS-C0Q10,
administered three weeks prior to PQ exposure and throughout the duration of the
experiment. Data have also shown that placebo does offer some protection against
oxidative stress; however placebo alone is not sufficient to protect the neurons from
undergoing neuronal death induced by PQ. The placebo formulation consists of vitaminE and poly ethylene glycol. Coenzyme Qio (C0Q10) on the other hand, works at the
mitochondrial level and does prevent neuronal cell death induced by PQ. The preliminary
studies using WS-C0Q10 as a therapeutic agent also showed the ability of this compound
to offer protection after inducing damage to the nigral cells with PQ. Despite statistical
lack of significance due to a small group of rats used in this study, this formulation has
shown that it can protect the rats against PQ toxicity.
My data adds to the mounting evidence that antioxidants, especially C0Q10 and
vitamin E, are important for the management of neurodegenerative diseases (McDonald
et al. 2005). Vitamin E has been tested for its potential as a neuroprotectant, however, it
proved to be a failure (Beal 2001). Neuroprotective effects of C0Q10 in the CNS has been
extensively evaluated (Beal and Matthews, 1997, Cleren et al. 2008) and numerous in
vivo studies demonstrate its protective role against experimental ischemia, sparing the
levels of GSH and ATP

(Beal 2003, Sikorska et al. 2003). CoQio is a highly

hydrophobic, naturally occurring compound that primarily functions in mitochondrial
membranes as a diffusible electron carrier of the mitochondrial respiratory chain
complexes. It is also a powerful antioxidant readily scavenging for free radicals (Beal
2003). Its pharmaceutical applications, however, seem to suffer from the lack of
solubility and low bioavailability, both which are needed to achieve therapeutic effect.
An open-label phase I clinical trial of CoQio in PD patients reveal good absorption and
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tolerance of C0Q10, however, very high dosages were required (up to 1200 mg per day) to
achieve some beneficial effects. Although very encouraging results were acquired from
this study, the authors express a concern that PD patients would have to take such a high
dosage of C0Q10- (Shults et al. 2002, Shults et al. 2004).
A recent study has shown that oil soluble Tishcon CoQio formula provided significant
protection against MPTP toxicity in a mouse model (Cleren et al. 2008). However the
effective doses used in this work were 200 mg/kg/day -1600 mg/kg/day (equivalent to 14
g/day-114 g/day for a 70 kg patient). This dose is extremely high and unlikely to be used
in human patients. On the other hand the effective daily dose of water soluble formulation
used in my study that offered significant neuroprotection is 5 mg/kg/day in rats, roughly
one fourth of the dose used in the aforementioned clinical trial and 40 times less than the
dose used by (Cleren et al. 2008) in mice. The more recently developed water soluble
formulation of CoQio (WS-CoQio) has been reported to be more effective as it combines
two potent antioxidants, i.e., derivatised vitamin E (PTS) and CoQio (Sikorska et al.
2003, Borowy-Borowski et al. 2004, www.Zymes.com). PTS is a pro-drug form of
vitamin E (a-tocopherol), which was chemically derivatised by sebacic acid and
polyethyleneglycol (PEG) and used a component (carrier) in WS-CoQio formulation
(Sikorska et al. 2003). These two compounds form a stable and water soluble complex
thereby causing them to be easy to deliver and test (i.e., in drinking water). The effective
daily dose of this formulation that offered significant neuroprotection in our study will
translate to 350 mg/day for a 70 kg human subject (roughly one fourth of the dose used in
the aforementioned clinical trial). Furthermore, rats fed with the WS-CoQio containing
diet have shown elevated plasma levels of CoQio (Sikorska et al. 2003). Due to the
water-soluble nature of our formulation, I have done extensive work on its effect as
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neuroprotective agent in neuronal cell cultures (Sandhu et al. 2003, McCarthy et al. 2004,
Somayajulu et al. 2005). In my previous in vitro studies I have shown that this
formulation of CoQio protects differentiated SHSY-5Y cells against PQ toxicity by
stabilizing mitochondrial membranes, maintaining mitochondrial membrane potential and
sustaining ATP production (McCarthy et al. 2004). More recently, I established that it
inhibits Bax activity and prevents Bax-induced destabilization of mitochondria in
mammalian cells (Naderi et al. 2006). Thus this formulation has advantages over the
current formulations being used.

4.7 Elucidating the Probable Mechanism of Neuroprotection by WS-CoQio.
Studies using PQ have shown that WS-CoQio can offer neuroprotection in vivo.
This formulation decreased the numbers of DA neurons undergoing cell death as well as
protected against PQ-induced oxidative stress and subsequent mitochondrial dysfunction.
In vitro studies have shown that WS-CoQio can offer neuroprotection against glutamate
toxicity, PQ toxicity and also hydrogen peroxide induced toxicity (Sandhu et al. 2003,
McCarthy et al. 2004, Somayajulu et al. 2005).
This raises the question: Is the neuroprotective ability of WS-CoQio solely based
on the fact that it is acts as an anti-oxidant? However, this is not the case. It has been
observed that when only the reduced formulation of CoQio is used as a neuroprotective
agent, it is toxic to the cells and could not protect them against oxidative stress (Sikorska
et al. personal communication). Interestingly, results using equimolar concentrations of
reduced and oxidized forms of CoQio offered neuroprotection against oxidative stress and
other apoptotic inducing agents. Vitamin-E and polyethylene glycol are used as carriers
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to solubilize C0Q10 and help in the uptake of this compound by the cells. Studies aimed at
evaluating the bioavailability of this formulation established that cells were capable of
internalizing WS-C0Q10 when it was added to the media as an aqueous solution (BorowyBorowski et al. 2004). A 3-day exposure tolO jug/ml of WS-C0Q10, caused an increase in
cellular mitochondrial membranes from 13.3 ng/106 cells to 27.5 ng/106 cells and an
increase in membranes from 0.7 to 6.0 ng/106 cells. The treatment also caused an increase
in total cellular levels of ATP as compared to untreated cells (Sandhu et al. 2003). This
formulation also further resulted in the prevention of mitochondrial collapse under
oxidative stress induced by PQ in vitro (McCarthy et al. 2004). These studies have
indicated that this formulation does enter the mitochondrial membrane and stabilize the
mitochondrial membrane by increasing the efficiency of the electron transport chain
(ETC). If the electrons are transferred efficiently via ETC, then the conversion of oxygen
to superoxide anion radical can be prevented. Our studies using isolated mitochondria
have shown that WS-CoQio can offer neuroprotection against rotenone and PQ-induced
toxicity (Figure 3.21).
More interestingly, in vitro studies have indicated that WS-CoQio can prevent
cells from Bax-induced mitochondrial damage (Figure 3.22) (Naderi et al. 2006). Recent
studies have reported the involvement of Bak in mediating the toxicity of PQ (Fei et al.
2008). Bax belongs to the family of pro-apoptotic factors which also include Bad, Bax,
Bid, Bak and Bim amongst others and can permeabilize the outer mitochondrial
membrane or bind to the voltage dependent anionic channel (VDAC) and cause the
opening of this channel. VDAC is a component of the mitochondrial permeability
transition pore (PTP). Bax binding therefore can lead to the leakage of cytochrome c, and
other factors from the mitochondria to the cytosol, which can induce apoptosis (Naderi et
131

al. 2006). Two mechanisms of neuroprotection by WS-C0Q10 are possible in this
scenario: (1) WS-C0Q10 can associate with Bax and prevent its binding to mitochondria
and (2) WS-CoQio can bind to the VDAC and prevent the binding of Bax to the channel.
Previous studies have shown that there are ubiquinone binding sites on the PTP.
Furthermore, binding of ubiquinone to PTP can inhibit the opening of the pore (Fontaine
etal. 1998).
Results from my study indicate that PQ as well as PQ-WS-CoQio may cause the
activation of astroglia, a feature of neuroinflammation. Therefore it is speculated that
WS-CoQio can cause astrocyte activation, which could be that be neuroprotective.
However, I do not have sufficient data for extrapolation currently.

4.8 Role of Astroglial Activation in Neuronal Cell Death and Neuroprotection
There appears to be a great amount of communication between neurons and non
neuronal milieu. Astrocytes are the most abundant cell type in the CNS and provide an
essential metabolic support to neurons, including regulation of ion homeostasis, GSH
metabolism, free radical scavenging and regulation of the blood-brain barrier. GSH acts
as an important intracellular antioxidant due to its ability to detoxify lipid and organic
peroxides including peroxynitrite. Activation of glial cells in the CNS in response to
injuries or neuropathological processes is well known and documented phenomenon,
although not always linked to neuroprotection (Eddleston and Mucke 1993, Drukarch et
al. 1998, Hailer et al. 2001, Liberto et al. 2004, Hanisch 2007) Although preliminary, I
have observed in this study, the activation of astrocytes in all the PQ-treated groups after
GFAP-immunostaining (Figure 3.17) as well as an increased expression of this protein in
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western blot analysis (Figure 3.12). Results from my study are intriguing because
astrocyte activation was also increased in PQ-WS-C0Q10 treated animals. Surprisingly,
the levels of activated astrocytes were not reduced in the presence of WS-CoQio- This
suggests that WS-CoQio may cause the release of neuroprotective cytokines and this is
novel (Figure 31). I observed an increase in the expression of the cytokine L-Selectin or
CD26L/LECAM-1. Further studies are needed to completely understand the
neuroprotective role of inflammation in PD, while using WS-CoQio as a neuroprotectant.
Activated astrocytes produce neurotrophic factors (i.e., Nerve growth factor
(NGF), Glial cell derived neurotrophic factor (GDNF), brain derived neurotrophic factor
(BDNF), cytokine ciliary neurotrophic factor or CNTF), scavenge excess of neurotoxic
glutamate and may provide energy substrates for neurons and perform the
neuroprotective function. For example, astrocytes store and subsequently metabolize
glycogen to sustain their own energy requirements. They can also export glucose and/or
lactate to support energy demands of neighbouring neurons (Dringen et al. 1993,
Brucklacher et al. 2002). My data is consistent with this scenario as the brain steady-state
ATP content remained unchanged in PQ-treated rats under the neuroprotective
conditions. In addition, astrocytes are equipped with a robust antioxidant system and
play a major role in GSH metabolism and neuroprotection (Peuchen et al. 1997, Wilson
1997, Dringen et al. 2000, Drigen and Hirrlinger 2003). PQ exposure causes a timedependent increase in the number of cells with immunohistochemical and morphological
features of activated microglia (Purisai et al. 2007). Multiple treatments with PQ or PQ
and maneb have been associated with activation of microglia, although the relationship
between this effect and neurodegeneration has yet to be demonstrated (McCormack et al.
2002, Saint-Pierre et al. 2006).
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4.9 Conclusions
In this study, I have successfully induced neuronal loss specific to the SNc in
Long Evan's hooded rats by 10 mg/kg PQ treatment. Results have revealed that PQ
induces oxidative stress, mitochondrial dysfunction, astrocyte activation as well as
reduced motor function. More significantly, I have observed that WS-C0Q10 offers
protection against PQ-mediated toxicity by not only preventing neuronal loss but also,
offering defense against oxidative stress, mitochondrial dysfunction and improves motor
function both as a prophylactic and therapeutic agent. Furthermore, in vitro studies
revealed protection against mitochondrial damage induced by rotenone, PQ and Bax. PD
is diagnosed usually after a substantial loss of DA neurons has occurred. The aim of this
study is to protect the remaining neurons from undergoing cell death and thus improving
the quality of life of PD patients. This study is, in fact, the first pre-clinical evaluation of
WS-C0Q10 as a neuroprotective (prophylactic) agent as well as therapeutic (restorative)
agent to prevent the loss of DA neurons.

4.10 Future work
Majority of the time and effort was spent on standardizing the protocols for
immunohistochemistry, behavioural studies and the biochemical studies. Results obtained
from the second phase of the study were performed using fewer numbers of rats. These
preliminary studies need to be repeated in order to obtain statistically significant data.
Also, using a larger sample of rats will be beneficial to minimize the issue of variability
in how the rats respond to PQ treatment.
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This work has significance for finding neuroprotective strategies to arrest the
progressive loss of DA neurons in PD. Interestingly, under all circumstances; I have
observed the neuroprotective ability of WS-CoQio- I have initiated the experiments to
evaluate the role of this formulation as a therapeutic agent. Therapy for PD begins after
diagnosis, by which time a large number of DA neurons have already been lost. For a
candidate to be considered as a good therapeutic/ restorative agent, it should be able to
arrest the further loss of neurons and thereby prevent the progression of this disease.
Further experiments will be needed to confirm our studies aimed at evaluating the
potential effects of WS-CoQio as a therapeutic intervention in PD (post-injection
feeding). Also, the experiments analyzing the effects of age on neuronal loss as well as
neuroprotection by WS-CoQio need to be thoroughly investigated. Many of the
biochemical and immunohistochemical assays need to be repeated due to small sample
size used in the current experiments.
Bioavailablity of WS-CoQio is very important because it is essential to know
how much of WS-CoQio can cross the blood brain barrier. Therefore the bioavailability
of WS-CoQio in the brain tissue as well as the mitochondria in neuronal cells will be
evaluated. The next set of experiments will include determining levels of WS-CoQio in
the brain and neuronal mitochondria by HPLC. Toxicopathology of WS-CoQio needs to
be performed to determine if it is safe for human consumption as this compound is a
potential candidate for clinical trials.
Of equal importance is to determine the levels of striatal dopamine and its
metabolites in PQ treated rats because one of the neurochemical features of PD is the loss
of dopamine in the striatum. HPLC will be used to determine the levels of striatal
dopamine and its metabolites.
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Further studies need to be performed to reveal the role of neuroinflammation in
development of this disease. Preliminary studies have revealed astrocyte activation in
PQ-WS-CoQio treated groups. There is a significant implication, and to analyze under
what circumstances inflammation is protective or toxic is very important.
Behavioural data for the second phase of the study is currently being compiled.
Furthermore, new tests are being standardised to assess behavioural impairment. Several
clinical studies have reported that exercise and balance training in the early stages of PD
improves overall muscle strength, balance, motor performance, and ambulation in
patients (Miyai et al. 2000, Bergen et al. 2002, Hassen et al. 2004). A recent study on
mouse model of PD has shown that endurance exercise training effectively reversed PDlike behavioral deficits related to regular movement and balance (Konstantinos et al.
2009). Therefore, studies will be aimed at testing if endurance exercise training might
enhance the effectiveness of WS-CoQIO treatment.
Finally, the mechanism of protection of WS-CoQio needs to be elucidated.
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Appendix A
Rat Injections
Animals are injected once a week with either saline or lOmg/kg paraquat.
Injection regimes usually begin a month after the animals arrive and have been handled
and put on different water regimens. Injections are performed in the Biology building
(basement: room adjacent to 72). Solutions and supplies are taken to the Biology building
from Essex Hall. Two people are required for injections: one for holding the animal
(properly and firmly), and the other for injecting the animal. Mr. Jouseph Barkho is
currently the person who holds the animals during injections. Efforts are made to ensure
that animals experience minimal discomfort, pain and distress during the injection
process. Ms. Elaine Rupke can train/ show a person how to inject intraperitonially in the
proper way without causing pain or stress to the animals. Following are the steps taken to
make the process convenient.
1. Make up a schedule and choose a preferable day and time for injections.
2. Make 10 mg/ml paraquat in phosphate buffered saline (PBS) pH= 7.6 (recipe in
materials and methods) and carry 5 ml of PBS pH=7.6. Make sure to label tubes
correctly.
3. Weigh the animals and record weights.
c/o

4. Use a syringe with a 25G needle and draw up the required volume.
5. Ensure that there are no air bubbles.
6. Place the animal in the position favourable for injection. Joe always flips the
animals upside down and holds the base of the chin and the hind legs.
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7. Inject the animal on the right side (in the area lower than the rib cage and above
the hind leg). Inject saline animals first.

NOTE: PQ is a very toxic chemical and needs to be handled with extreme
caution. Wear a labcoat. facemask and gloves while using PO and discard the
gloves after use in the biohazard bag. Also, wash your hands thoroughly with
soap and water.

167

Appendix B

Perfusion and Dissections
All dissections are performed in the dissection room in the animal facility (room 72)
located in the basement of the Biology building.

Equipment Preparation
1. Gloves, labcoat and protective eyewear must be worn during this
procedure.
2. A uume hood with sufficient room for equipment and working exhaust
system.
3. Perfusion rack, isofurane (anaesthetic) and oxygen cylinder (make sure it
is not empty).
4. Perfusion kit consisting of:
•

4 pairs scissors (2 blunt and 2 sharp), 5 sets of forceps: toothed,
serrated, coverglass forceps bent, smooth jaw forceps, bone cutting
forceps.

•

Needles (20G1, with short bevel work best for most rats).

•

Perfusion apparatus (2 clean bottles: one labelled tyrodes and other
formaldehyde, clean tubes and clasps).

5. Labelled tubes (50 ml), 70% ethanol solution in a spray bottle, 2L
containers for storing fixative solution as well as Tyrode's solution with
heparin
Fixatives: 10% Formaldehyde in 0.1 M PBS solution pH=7.6.
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Before you start, check the checklist.
Checklist:
Things to bring from Essex Hall:
1. Tyrode's stock solution
2. Heparin (added) ?
3. 10% buffered Formaldehyde stock
4. Labelled Tubes (rat numbers and cage numbers, date, organ type and batch),
forceps, scissors, isofurane, ethanol, paper towels, biohazard bags (orange
coloured)
In the animal facility:
• Oxygen cylinder, garbage bag for collecting carcasses and the bottles for
perfusion.
•

Animal care technician informed

Procedure
•

Fill the two bottles with corresponding liquids, adjust the tubing and the flow rate
to 30 ml/minute and ensure no air bubbles are present through the tubing. No
formalin should be present in the tubing when you start. Rinse the tubing with
Tyrode's.

• Weigh the rat and place it into the plastic chamber used for anaesthetising
animals. Turn on the anaesthetic pump and the oxygen cylinder. Anaesthetize the
rat into a deep surgical plane. As this is a terminal procedure, it is important that
the rat be very deeply anaesthetized, but the heart must still be beating. This
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process takes upto 7-8 minutes, after which the rat will stop moving in the
chamber.
•

Put the rat into the dissecting tray. Quickly, put the nozzle on the rat's nose and
hold it in place.

• Two people are required for this step: One person is responsible for dissections
while the other person assists (holds the nozzle, helps switch liquids, hands
equipment needed to the person dissecting).
• Check to make sure the rat is deeply anaesthetized (usually by pinching one of the
hind legs with a pair of forceps). If the animal retracts its foot, then put it back in
the chamber for an additional 5-7 minutes.
• Spray animal with 70 % ethanol so that the fur doesn't stick to the insides after
cutting and it is easy to clean fur from the scissors and forceps.
•

Make vertical surgical cut along the chest midline to below the rib cage by pulling
up flesh with a pair of toothed forceps and cutting with blunt scissors.

• Using a pair of toothed forceps pinch the sternum and pull up (white cartilage
flap) and cut through the diaphragm.
The rest of this procedure must be done quickly to make sure the heart continues to
pump the blood.
• Whilst holding the sternum with toothed forceps the in one hand, make lateral
cuts bisecting ribs on both sides of animal towards armpits.
• Pull up the rib cage exposing the liver, stomach and heart.
• Introduce the needle into the left ventricle (on your right as you look down),
making sure not to pierce through to the left atrium all the way into the aorta. This
will be the entrance site for the saline and formaldehyde.
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• Start pumping the Tyrode's solution and make a small cut on the lobe of the liver
to allow the blood, saline and the formaldehyde to leave the body during
perfusion.
•

The liver should become pale as the blood drains. Within 30 seconds there should
be some muscle twitching. Be careful to keep the needle in place all while this
occurs. The person assisting can hold the tail and the legs to help keep the animal
in place.

• Turn of the isofurane and remove the nozzle from the nose at this point.
•

Allow blood to drain; the liquid as it is pumped through will change from dark red
to clear if the procedure is done properly.

• Switch the solutions and run the fixative through the animal. Once the front paws
are stiff (150-200ml of fixative), then turn off the fixative. Remove needle from
heart. Pour out any liquid left in the rat's chest cavity.
•

Place the rat in the guillotine and remove head for the brain to be harvested.

•

Fix the brain after surgery. For immunocytochemistry for 24 hours then switch to
70% ethanol and store in 2-8°C.

• Clean the apparatus thoroughly with antibacterial reagent and wipe down the
work area. Turn off the O2 cylinder. Shut down the fiimehood. Place the carcasses
into the cold room (biology basement, just opposite Ms. Rupke's office).
Autoclave the biohazard bag in Essex Hall before disposing the waste.
The different apparatus used in this experiment is shown below.
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1. Perfusion Apparatus

1054 Formalin
flap to keep bottles secure

Tyrode's Solution

Clasp to regulate the Row of
tyrode's solution
Clasp to regulate the flow of
formalin

Needle for
perfusion
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Vapourizer for Isoflurane
Valve to turn on
die flow of
4^
anesthetic
Knob (pressed
downwards) to
rotate the valve

Level at which the red
button needs to be
during perfusion

Level to which the
isofurane must be 4r
filled
Red button indicates ^
oxygen level

Knob to adjust red
button
*
Knob that
controls the
inlet for filling
up isofurane

Appendix C

Rat Tissue Snap Freezing
All dissections are performed in the dissection room in the animal facility (room 72)
located in the basement of the biology building.
Equipment Preparation
•

Gloves, lab coat and protective eyewear should be worn during this procedure

•

A fume hood with sufficient room for equipment and working exhaust system

•

Dry ice, liquid nitrogen and carbon dioxide cylinder (make sure it is not empty)

•

Dissection kit consisting of:
4 pairs scissors (2 blunt and 2 sharp), 5 sets of forceps: toothed,
serrated, coverglass forceps bent, large forceps bent, bone cutting
forceps

•

Guillotine

•

Clean labelled tubes

Before you start, check the checklist.
Checklist:
Things to bring from Essex Hall:
•

Dry ice

•

Liquid Nitrogen

•

Labelled Tubes, forceps, scissors, ethanol, paper towels, bags for collecting
carcasses and biohazard bags (orange coloured)
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In the animal facility:
•

Carbon dioxide cylinder, garbage bag for collecting carcasses

•

Animal care technician should be informed about the dissections

Procedure
•

Weigh the rat and place it into the gas chamber. Turn the nozzle on the CO2
cylinder so that the gas flows into the chamber. The first rat will take about 5-6 to
minutes to "fall asleep." (Once the chamber is filled with CO2, the other rats take
less time) Wait till the rat stops moving in the chamber. Make sure that the rat is
"asleep" by checking the heart beat and by giving an obnoxious stimulus to the
hind leg. Make sure that the exhaust tube for the chamber is in the fumehood and
the fan is on.

•

Put the rat into the guillotine and swiftly decapitate.

•

Two people are required for this step: One person is responsible for dissecting the
brain and flash freezing tissues while the other person is responsible for dissecting
the other organs i.e. liver, lungs, heart, spleen and kidneys and passing them onto
the person responsible for flash freezing.

• Spray animal with 70 % ethanol so that the fur doesn't stick to the insides after
cutting and it is easy to clean for from the scissors and forceps.
•

Make vertical surgical cut along the chest midline to below the rib cage by pulling
up flesh with a pair of toothed forceps and cutting with blunt scissors.

•

Using a pair of toothed forceps pinch the sternum and pull up (white cartilage
flap) and cut through the diaphragm.
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Whilst holding the sternum with toothed forceps the in one hand, make lateral
cuts bisecting ribs on both sides of animal towards armpits.
Pull up the rib cage exposing the liver, stomach and heart.
Cut a small piece of the liver, mince it fine with the scalpel and flash freeze (make
sure that the tissue is frozen and there is no liquid nitrogen in the tube when you
place the cap on it. Follow these steps inside the fumehood and lower the barrier
while dealing with liquid nitrogen. These steps require caution)
Follow the same with the heart, lungs, kidneys and spleen.
Meanwhile dissect the brain and make a coronal cut just at the base of the optic
chiasm and remove the cerebellum. This procedure has been followed for the 5
injection regime (for 3 injection animals, the striatum was separated from the
substantia nigra region before freezing).
Freeze each part separately.
Place the tissues on dry ice. Bring the tissues back to Essex Hall. Place the tubes
in labelled Ziploc bags and place them in -80°C in Dr. Mutus' lab in the shelf
allotted to the Pandey lab.
Clean the apparatus thoroughly with antibacterial reagent and wipe down the
place. Turn off the CO2 cylinder. Shut down the fumehood. Place the carcasses
into the cold room (Biology basement, just opposite Ms. Rupke's office).
Autoclave the biohazard bag in Essex Hall before disposing the waste.
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The different apparatus used in this experiment is shown below.

1. CO2 chamber

2. Guillotine
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Appendix D
Paraffin Embedding and Sectioning on the Microtome
Paraffin embedding and sectioning are performed in Essex 282-1.
Equipment Preparation
• Wear gloves, labcoat and protective eyewear during this procedure
•

Two 50 ml tubes with melted Paraffin

• Embedding rings and steel moulds for preparing paraffin blocks
•

Microtome

•

Water bath at 60°C for embedding and 40°C for sectioning

•

Fresh 70%, 80%, 95% and anhydrous ethanol (EtOH) and xylene

•

Blades for microtome

Procedure
•

Trim the tissue. For the second phase study, we placed a coronal cut at the optic
chaism and cut the brain into two pieces and saved both the pieces. (Please refer
to the picture below). For the first phase of the study, a 3-4 mm piece was
obtained as shown in the picture and processed.

During phase 1 study

Tissue of interest

During the phase 2 study
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Tissue of interest

The tissue of interest was then processed for paraffin embedding. For the 5
injection study, the tissue is incubated with following solutions:
1. Fresh 70% EOH for 1 hour
2. 80% EOH for 1 hour
3. 95% EOH for 1 hour
4. Anhydrous EOH for 3 hours
5. Xylene 1 hour and 15 minutes
6. Rinsed with melted paraffin and then placed in paraffin overnight in the water
bath at 60°C
Tissues were placed in a steel mould, paraffin was poured, and tissue of interest
was placed in the mould, followed by the embedding ring and finally topped off
with paraffin.
The paraffin was allowed to solidify (3-4 hours at room temperature) and the
mould was turned upside down and gently tapped with a pair of forceps to obtain
the paraffin embedded tissue (block) was obtained.
The block was then placed on the microtome, secured and the position was
adjusted for obtaining sections.
Initially the microtome is set at about 40 microns and the block is sectioned at this
thickness till tissue starts appearing in the wax ribbon.
The tissue is then trimmed at 20 microns and a stereotaxic rat atlas is referred to
until the region of interest is reached (Figure 70- the substantia nigra pars
reticulate is seen).
Once the region of interest is reached, 6 sections are taken at 8 microns.
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•

A ribbon of 6 sections is placed in the water bath at 40°C and allowed to stretch.

•

A slide is used to scoop up 4 sections and then placed in a trough and dried at
room temperature overnight.

• Sections are taken across the whole substantia nigra region and put onto slides.
• The slides are labelled (correctly: cage number, rat number e.g.1-1, batch slide
numbers as l,2...n ) and placed in a plastic slide box that holds 100 slides until
required at room temperature.
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